<SEC-DOCUMENT>0001493152-21-014657.txt : 20210617
<SEC-HEADER>0001493152-21-014657.hdr.sgml : 20210617
<ACCEPTANCE-DATETIME>20210617161529
ACCESSION NUMBER:		0001493152-21-014657
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20210617
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210617
DATE AS OF CHANGE:		20210617

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HARROW HEALTH, INC.
		CENTRAL INDEX KEY:			0001360214
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				450567010
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35814
		FILM NUMBER:		211024921

	BUSINESS ADDRESS:	
		STREET 1:		102 WOODMONT BLVD
		STREET 2:		SUITE 610
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37215
		BUSINESS PHONE:		615.733.4731

	MAIL ADDRESS:	
		STREET 1:		102 WOODMONT BLVD
		STREET 2:		SUITE 610
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37215

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Imprimis Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20120301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSDEL PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20070912

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bywater Resources, Inc
		DATE OF NAME CHANGE:	20060421
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:HROW="http://harrowinc.com/20210617">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_HROW_harrowinc.com_20210617 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20210617_20210617 -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001360214 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-06-17to2021-06-17" name="dei:EntityCentralIndexKey">0001360214</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-06-17to2021-06-17" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="hrow-20210617.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-06-17to2021-06-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-17</xbrli:startDate>
        <xbrli:endDate>2021-06-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-172021-06-17_custom_CommonStock0.001ParValuePerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">HROW:CommonStock0.001ParValuePerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-17</xbrli:startDate>
        <xbrli:endDate>2021-06-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-172021-06-17_custom_Sec8.625SeniorNotesDue2026Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-17</xbrli:startDate>
        <xbrli:endDate>2021-06-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>FORM
<span id="xdx_906_edei--DocumentType_c20210617__20210617_zE3tUeYDiKOj"><ix:nonNumeric contextRef="From2021-06-17to2021-06-17" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Date
of Report (Date of earliest event reported): <span id="xdx_901_edei--DocumentPeriodEndDate_c20210617__20210617_zBVzvepiX9ji"><ix:nonNumeric contextRef="From2021-06-17to2021-06-17" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 17, 2021</ix:nonNumeric></span> (June 14, 2021)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b><span id="xdx_905_edei--EntityRegistrantName_c20210617__20210617_zT17g3rEWz0j"><ix:nonNumeric contextRef="From2021-06-17to2021-06-17" name="dei:EntityRegistrantName">HARROW
HEALTH, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20210617__20210617_zcG87Tlj8LC6"><ix:nonNumeric contextRef="From2021-06-17to2021-06-17" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_909_edei--EntityFileNumber_c20210617__20210617_z6VXp4CH5tlb"><ix:nonNumeric contextRef="From2021-06-17to2021-06-17" name="dei:EntityFileNumber">001-35814</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20210617__20210617_zIfXkBxvH4e9"><ix:nonNumeric contextRef="From2021-06-17to2021-06-17" name="dei:EntityTaxIdentificationNumber">45-0567010</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State
    or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">of
    incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">File
    Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(IRS
    Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 66%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90C_edei--EntityAddressAddressLine1_c20210617__20210617_zSVS7vjAgqsl"><ix:nonNumeric contextRef="From2021-06-17to2021-06-17" name="dei:EntityAddressAddressLine1">102
    Woodmont Blvd.</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressAddressLine2_c20210617__20210617_z5i2sHykjH1f"><ix:nonNumeric contextRef="From2021-06-17to2021-06-17" name="dei:EntityAddressAddressLine2">Suite 610</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_901_edei--EntityAddressCityOrTown_c20210617__20210617_zAhkE3IjX6ec"><ix:nonNumeric contextRef="From2021-06-17to2021-06-17" name="dei:EntityAddressCityOrTown">Nashville</ix:nonNumeric></span>,
    <span id="xdx_903_edei--EntityAddressStateOrProvince_c20210617__20210617_zltQL6goxg16"><ix:nonNumeric contextRef="From2021-06-17to2021-06-17" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Tennessee</ix:nonNumeric> </span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90C_edei--EntityAddressPostalZipCode_c20210617__20210617_z4zt2K0WowN"><ix:nonNumeric contextRef="From2021-06-17to2021-06-17" name="dei:EntityAddressPostalZipCode">37205</ix:nonNumeric></span></b></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Zip
    Code)</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Registrant&#8217;s
telephone number, including area code: <b><span id="xdx_90C_edei--CityAreaCode_c20210617__20210617_zqTumFVAKwjh"><ix:nonNumeric contextRef="From2021-06-17to2021-06-17" name="dei:CityAreaCode">(615)</ix:nonNumeric></span> <span id="xdx_902_edei--LocalPhoneNumber_c20210617__20210617_zk2UfROqu6c2"><ix:nonNumeric contextRef="From2021-06-17to2021-06-17" name="dei:LocalPhoneNumber">733-4730</ix:nonNumeric></span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="padding-bottom: 1.5pt; width: 20%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 60%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Not
    Applicable</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 20%">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Former
    Name or Former Address, if Changed Since Last Report)</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Name
    on exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_edei--Security12bTitle_c20210617__20210617__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.001ParValuePerShareMember_zjvBrjKYjbe8"><ix:nonNumeric contextRef="From2021-06-172021-06-17_custom_CommonStock0.001ParValuePerShareMember" name="dei:Security12bTitle">Common Stock, $0.001 par value per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--TradingSymbol_c20210617__20210617__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.001ParValuePerShareMember_zVbzdh1vAaf"><ix:nonNumeric contextRef="From2021-06-172021-06-17_custom_CommonStock0.001ParValuePerShareMember" name="dei:TradingSymbol">HROW</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span>The
    <span id="xdx_90C_edei--SecurityExchangeName_c20210617__20210617__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.001ParValuePerShareMember_zCmujsDKsJK5"><ix:nonNumeric contextRef="From2021-06-172021-06-17_custom_CommonStock0.001ParValuePerShareMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Global Market</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--Security12bTitle_c20210617__20210617__us-gaap--StatementClassOfStockAxis__custom--Sec8.625SeniorNotesDue2026Member_zGGnYxXNBbXc"><ix:nonNumeric contextRef="From2021-06-172021-06-17_custom_Sec8.625SeniorNotesDue2026Member" name="dei:Security12bTitle">8.625% Senior Notes due 2026</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_edei--TradingSymbol_c20210617__20210617__us-gaap--StatementClassOfStockAxis__custom--Sec8.625SeniorNotesDue2026Member_zfGxCFn9uYck"><ix:nonNumeric contextRef="From2021-06-172021-06-17_custom_Sec8.625SeniorNotesDue2026Member" name="dei:TradingSymbol">HROWL</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span>The
    <span id="xdx_901_edei--SecurityExchangeName_c20210617__20210617__us-gaap--StatementClassOfStockAxis__custom--Sec8.625SeniorNotesDue2026Member_z5atluX9fPU1"><ix:nonNumeric contextRef="From2021-06-172021-06-17_custom_Sec8.625SeniorNotesDue2026Member" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Global Market</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_edei--WrittenCommunications_c20210617__20210617_z1jzrjVog2ef"><ix:nonNumeric contextRef="From2021-06-17to2021-06-17" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_edei--SolicitingMaterial_c20210617__20210617_z4IiJscUTEL5"><ix:nonNumeric contextRef="From2021-06-17to2021-06-17" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_edei--PreCommencementTenderOffer_c20210617__20210617_zXhqVyOIBLq3"><ix:nonNumeric contextRef="From2021-06-17to2021-06-17" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--PreCommencementIssuerTenderOffer_c20210617__20210617_zryENLIVYtDa"><ix:nonNumeric contextRef="From2021-06-17to2021-06-17" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2
of the Securities Act of 1934: Emerging growth company <span id="xdx_908_edei--EntityEmergingGrowthCompany_c20210617__20210617_zSMLNZO6N4Bh"><ix:nonNumeric contextRef="From2021-06-17to2021-06-17" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
any emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
1.01 Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
June 14, 2021, Harrow Health, Inc. (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;) entered into an underwriting agreement (the &#8220;<span style="text-decoration: underline">Underwriting
Agreement</span>&#8221;) with B. Riley Securities, Inc., as representative of the several underwriters named therein (the &#8220;<span style="text-decoration: underline">Underwriters</span>&#8221;),
pursuant to which the Company agreed to sell to the Underwriters $17,500,000 aggregate principal amount of 8.625% Senior Notes due 2026
(the &#8220;<span style="text-decoration: underline">Firm Notes</span>&#8221;) plus up to an additional $2,500,000 aggregate principal amount of 8.625% Senior Notes due 2026
pursuant to an option to purchase additional Notes (the &#8220;<span style="text-decoration: underline">Additional Notes</span>&#8221;, and together with the Firm Notes, the
&#8220;<span style="text-decoration: underline">Notes</span>&#8221;). The Notes are a further issuance of 8.625% senior notes due 2026, of which $55,000,000 aggregate principal
amount was outstanding prior to the offering (the &#8220;<span style="text-decoration: underline">Existing Notes</span>&#8221;). The Notes are treated as a single series with
the Existing Notes under the indenture governing the Existing Notes, dated as of April 20, 2021 (the &#8220;<span style="text-decoration: underline">Base Indenture</span>&#8221;),
as supplemented by the First Supplemental Indenture, dated as of April 20, 2021 (the &#8220;<span style="text-decoration: underline">First Supplemental Indenture</span>&#8221;),
by and between the Company and U.S. Bank National Association, as trustee, with respect to the Notes (collectively, the &#8220;<span style="text-decoration: underline">Indenture</span>&#8221;)
and have the same terms as the Existing Notes (other than the initial offering price and the issue date). The Notes have the same CUSIP
number and trade interchangeably with the Existing Notes. The Notes and the Existing Notes are fungible for U.S. federal income tax purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Notes were offered pursuant to the Company&#8217;s shelf registration statement on Form S-3 (Registration No. 333-239669), which was
declared effective by the Securities and Exchange Commission (the &#8220;<span style="text-decoration: underline">Commission</span>&#8221;) on July 13, 2020 (the &#8220;<span style="text-decoration: underline">Registration
Statement</span>&#8221;). On June 14, 2021, the Company priced the offering and on June 16, 2021, the Underwriters exercised their option
to purchase the Additional Notes. On June 17, 2021, the offering of the Notes closed. The Notes were sold to investors at a price of
$25.75 per Note and the offering resulted in net proceeds to the Company of approximately $19.6 million after deducting underwriting
discounts and commissions, but before expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Underwriting Agreement contains customary representations, warranties and covenants of the Company, customary conditions to closing,
indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended,
other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting
Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such
agreement, and may be subject to limitations agreed upon by the contracting parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
foregoing description of the material terms of the Underwriting Agreement is qualified in its entirety by reference to the full text
of the Underwriting Agreement, a copy of which is attached hereto as <span style="text-decoration: underline">Exhibit 1.1</span> and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Notes are senior unsecured obligations of the Company and rank equally in right of payment with all of the Company&#8217;s other existing
and future senior unsecured and unsubordinated indebtedness. The Notes are effectively subordinated in right of payment to all of the
Company&#8217;s existing and future secured indebtedness and structurally subordinated to all existing and future indebtedness of the
Company&#8217;s subsidiaries, including trade payables. The Notes bear interest at the rate of 8.625% per annum. Interest on the Notes
is payable quarterly in arrears on January 31, April 30, July 31 and October 31 of each year, commencing on July 31, 2021. The Notes
will mature on April 30, 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Prior
to February 1, 2026, the Company may, at its option, redeem the Notes, in whole at any time or in part from time to time, at a redemption
price equal to 100% of the principal amount of the Notes to be redeemed, plus a make-whole amount that is further described in the First
Supplemental Indenture, if any, plus accrued and unpaid interest to, but excluding, the date of redemption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Company may redeem the Notes for cash in whole or in part at any time at our option on or after February 1, 2026 and prior to maturity,
at a price equal to 100% of their principal amount, plus accrued and unpaid interest to, but excluding, the date of redemption. On and
after any redemption date, interest will cease to accrue on the redeemed Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Indenture contains customary events of default and cure provisions. If an uncured default occurs and is continuing, the Trustee or the
holders of at least 25% of the principal amount of the Notes may declare the entire amount of the Notes, together with accrued and unpaid
interest, if any, to be immediately due and payable. In the case of an event of default involving the Company&#8217;s bankruptcy, insolvency
or reorganization, the principal of, and accrued and unpaid interest on, the principal amount of the Notes, together with accrued and
unpaid interest, if any, will automatically, and without any declaration or other action on the part of the Trustee or the holders of
the Notes, become due and payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
foregoing description of the Base Indenture, the First Supplemental Indenture and the Notes does not purport to be complete and is qualified
in its entirety by reference to the full text of the Base Indenture, the First Supplemental Indenture and the form of Note copies of
which are attached hereto as <span style="text-decoration: underline">Exhibit 4.1</span>, <span style="text-decoration: underline">Exhibit 4.2</span> and <span style="text-decoration: underline">Exhibit 4.3</span> and incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Attached
as <span style="text-decoration: underline">Exhibit 5.1</span> to this Current Report and incorporated herein by reference is a copy of the opinion of <span style="background-color: white">Waller
Lansden Dortch &amp; Davis, LLP</span>, relating to the validity of the Notes that may be sold in the offering (the &#8220;<span style="text-decoration: underline">Legal Opinion</span>&#8221;).
The Legal Opinion is also filed with reference to, and is hereby incorporated by reference into, the Registration Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
June 14, 2021, the Company issued a press release announcing the pricing of the offering. A copy of the press release is filed as <span style="text-decoration: underline">Exhibit
99.1</span> to this report and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
June 17, 2021, the Company issued a press release announcing the closing of the offering. A copy of the press release is filed as <span style="text-decoration: underline">Exhibit
99.2</span> to this report and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -58.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -58.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
information regarding the Notes and the Indenture set forth in Item 1.01 is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
8.01 Other Events.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
June 17, 2021, upon closing of the Note offering, the Company used approximately $11.1 million of the net proceeds from the sale of the
Notes to redeem all of the outstanding shares of the Company&#8217;s Series B Cumulative Preferred Stock, par value $0.001 per share.
The redemption price for the 440,000 shares of Series B Cumulative Preferred Stock outstanding was equal to $25.00 per share, plus accrued
and unpaid dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
9.01 Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">(d)</span></td>
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><span style="text-decoration: underline">Exhibits</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">1.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><a href="ex1-1.htm">Underwriting Agreement, dated as of June 14, 2021, by and among the Company and B. Riley Securities, Inc., as representative of the several underwriters named therein.</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">4.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315221009249/ex4-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Indenture, dated as of April 20, 2021, by and between the Company and U.S. Bank National Association, as Trustee (incorporated herein by reference to Exhibit 4.1 to the Current Report on Form 8-K of the Company filed with the SEC on April 20, 2021).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">4.2
    </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315221009249/ex4-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">First Supplemental Indenture, dated as of April 20, 2021, by and between the Company and U.S. Bank National Association, as Trustee (incorporated herein by reference to Exhibit 4.2 to the Current Report on Form 8-K of the Company filed with the SEC on April 20, 2021).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">4.3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315221009249/ex4-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Form of </span><span style="font: 10pt Times New Roman, Times, Serif">8.625<span style="background-color: white">% Senior Notes due 2026 (included in Exhibit 4.2). </span></span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">5.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><a href="ex5-1.htm">Opinion of Waller Lansden Dortch &amp; Davis, LLP.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">23.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex5-1.htm"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Consent of Waller Lansden Dortch &amp; Davis, LLP (included in Exhibit 5.1 hereto).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">99.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><a href="ex99-1.htm">Pricing Press Release, dated June 14, 2021.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">99.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><a href="ex99-2.htm">Closing Press Release, dated June 17, 2021.</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>HARROW
    HEALTH, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 47%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Dated:
    June 17, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Andrew R. Boll</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Andrew
    R. Boll</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Chief
    Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJydkdFKwzAUhp9g73Aoeje6tLo5eqdVh7iNso4hiBexPdOwNqecpNM9km9pmiLK0BtDIDT5vv4/SRAMgxndqgoZHq5Wc1hj3VTSIqxwi4y6QEekd/cJuHWFL8pYltr6zy8xJeegc8bhVLp9T+6VwTIBMRlFF6M4AnGWnI8hWwSD7jwlvVUlaqtkBVKXkDE1rNBKPvR/WMt30lQffNIG2SjSCUSh6I8/IBZRDEvayzfinYH5PA0GQz8GwYypbbqY1liq4abC2mWZXv2evkrhmSTHYhpO4nGOWhEvyaK5bjEW8WSB9TOyI4WIXehl1+BvGh57/slRHjmFHgJPQdkiHHPHXdyF1qRzS8VOhEJEmeSNrFrMkPNXyfhbo94BLw3hxHvQSIZ9Z0Lj3sl07s/c/zi+6ycKy6hS -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>EXECUTION
COPY</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HARROW
HEALTH</B>, <B>INC</B>.<B><BR>
8.625% SENIOR NOTES DUE 2026<BR>
<U>UNDERWRITING AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: right; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
14, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Riley Securities, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
representative of the several underwriters</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o
B. Riley Securities, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">299
Park Avenue, 21<SUP>st</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10171</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Health, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), proposes to issue and sell to the several Underwriters on <U>Schedule
A</U> hereto (the &ldquo;<B>Underwriters</B>&rdquo;), for whom B. Riley Securities, Inc. is acting as representative (in such capacity,
the &ldquo;<B>Representative</B>&rdquo;), $17,500,000 aggregate principal amount of 8.625% Senior Notes due 2026 (the &ldquo;<B>Firm
Notes</B>&rdquo;). In addition, the Company proposes to grant to the Underwriters the option to purchase from the Company up to an additional
$2,500,000 aggregate principal amount of 8.625% Senior Notes due 2026 (the &ldquo;<B>Additional Notes</B>&rdquo;). The Firm Notes and,
if and to the extent such option is exercised, the Additional Notes are hereinafter collectively referred to as the &ldquo;<B>Notes</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes will be issued under an indenture dated as of April 20, 2021 (the &ldquo;<B>Base Indenture</B>&rdquo;), as supplemented by the
First Supplemental Indenture dated as of April 20, 2021 (the &ldquo;<B>First Supplemental Indenture,</B>&rdquo; and together with the
Base Indenture, the &ldquo;<B>Indenture</B>&rdquo;), between the Company and U.S. Bank National Association as trustee (the &ldquo;<B>Trustee</B>&rdquo;).
The Notes will be issued to Cede &amp; Co., as nominee of the Depository Trust Company (&ldquo;<B>DTC</B>&rdquo;) pursuant to a blanket
letter of representations (the &ldquo;<B>DTC Agreement</B>&rdquo;) to be dated on or prior to the Closing Date (as defined herein), between
the Company and DTC. The Indenture will be qualified under the Trust Indenture Act of 1939, as amended (the &ldquo;<B>Trust Indenture
Act</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and the Underwriters agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>1.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>The Offering</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.
Upon the basis of the representations and warranties and subject to the terms and conditions herein set forth, the Company agrees to
issue and sell to the Underwriters, severally and not jointly, the aggregate principal amount of Firm Notes set forth opposite the name
of such Underwriter on <U>Schedule A</U>, and each of the Underwriters, severally and not jointly, agrees to purchase from the Company
at the price (the &ldquo;<B>Purchase Price</B>&rdquo;) set forth in <U>Schedule B</U> hereto the aggregate principal amount of Firm Notes
set forth opposite the name of such Underwriter on <U>Schedule A</U> subject to adjustment in accordance with <U>Section 7</U> hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Company hereby grants to the several Underwriters the option to purchase and, upon the basis of the representations and
warranties and subject to the terms and conditions herein set forth, the Underwriters shall have the right to purchase, severally and
not jointly, from the Company, ratably in accordance with the number of Firm Notes to be purchased by each of them, all or a portion
of the Additional Notes, at the same Purchase Price to be paid by the Underwriters for the Firm Notes (without giving effect to any accrued
interest from the Closing Date to the Additional Closing Date (as defined below)). This option may be exercised by the Representative
on behalf of the several Underwriters at any time and from time to time in whole or in part by written notice from the Representative
to the Company, which notice may be given at any time within 30 days from the date of this Agreement. Such notice shall set forth (i)
the aggregate principal amount of Additional Notes as to which the option is being exercised and (ii) the date, time and place at which
such Additional Notes are to be delivered (such date, the &ldquo;<B>Additional Closing Date</B>&rdquo; and such time of such date, the
&ldquo;<B>Additional Time of Purchase</B>&rdquo;); <I>provided</I>, <I>however</I>, that the Additional Time of Purchase may be simultaneous
with, but shall not be earlier than the Time of Purchase (as defined below) and shall not be earlier than two nor later than five full
business days after delivery of such notice of exercise. The aggregate principal amount of Additional Notes to be sold to each Underwriter
shall be the aggregate principal amount which bears the same proportion to the total aggregate principal amount of Additional Notes being
purchased as the number of Firm Notes set forth opposite the name of such Underwriter on <U>Schedule A</U> bears to the total aggregate
principal amount of Firm Notes, subject to adjustment in accordance with <U>Section 7</U> hereof. The Representative may cancel the option
at any time prior to its expiration by giving written notice of such cancellation to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>2.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations and Warranties of the Company</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.
The Company represents and warrants to, and agrees with, the Underwriters that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has prepared and filed in conformity with
the requirements of the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), and published rules and regulations
thereunder (the &ldquo;<B>Rules and Regulations</B>&rdquo;) adopted by the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;)
a &ldquo;shelf&rdquo; Registration Statement (as hereinafter defined) on Form S-3 (File No. 333-239669), which was declared effective
by the Commission as of July 13, 2020 (the &ldquo;<B>Effective Date</B>&rdquo;), including a base prospectus relating to the securities
registered pursuant to such Registration Statement (the &ldquo;<B>Base Prospectus</B>&rdquo;), and such amendments and supplements thereto
as may have been required to the date of this Agreement. The term &ldquo;<B>Registration Statement</B>&rdquo; as used in this Agreement
means the registration statement (including all exhibits, financial schedules and all documents and information deemed to be a part of
the Registration Statement pursuant to Rule 430B of the Rules and Regulations), as amended and/or supplemented to the date of this Agreement,
including the Base Prospectus. The Registration Statement is effective under the Securities Act, and no stop order preventing or suspending
the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus (as defined below) has been issued
by the Commission, and to the knowledge of the Company, no proceedings for that purpose have been instituted or are threatened by the
Commission. The Company has prepared a prospectus supplement to the Base Prospectus included as part of such registration statement specifically
relating to the Notes (the &ldquo;<B>Prospectus Supplement</B>&rdquo;) and has or will file such Prospectus Supplement with the Commission
pursuant to Rule 424(b) of the Rules and Regulations. The term &ldquo;<B>Prospectus</B>&rdquo; as used in this Agreement means the Base
Prospectus, as it may be supplemented by the Prospectus Supplement, in the forms in which such Base Prospectus or Prospectus Supplement
has been or is to be filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations, except that if any revised prospectus
or prospectus supplement shall be provided to the Underwriters by the Company for use in connection with the offering and sale of the
Notes (the &ldquo;<B>Offering</B>&rdquo;) which differs from the Prospectus (whether or not such revised prospectus or prospectus supplement
is required to be filed by the Company pursuant to Rule 424(b) of the Rules and Regulations), the term &ldquo;<B>Prospectus</B>&rdquo;
shall refer to such revised prospectus or prospectus supplement, as the case may be, from and after the time it is first provided to
the Underwriters for such use. Any reference herein to the Registration Statement or the Prospectus shall be deemed to refer to and include
the documents incorporated by reference therein pursuant to Item 12 of Form S-3 which were filed under the Securities Exchange Act of
1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), on or before the last to occur of the Effective Date, or the date of the Prospectus,
and any reference herein to the terms &ldquo;amend,&rdquo; &ldquo;amendment,&rdquo; or &ldquo;supplement&rdquo; with respect to the Registration
Statement or the Prospectus shall be deemed to refer to and include (i) the filing of any document under the Exchange Act after the Effective
Date or the date of the Prospectus, as the case may be, which is incorporated by reference and (ii) any such document so filed. If needed
to complete the Offering, the Company will file an abbreviated registration statement to register additional securities pursuant to Rule
462(b) under the Rules and Regulations (the &ldquo;<B>462</B>(<B>b</B>) <B>Registration Statement</B>&rdquo;), and any reference herein
to the Registration Statement shall also be deemed to include such 462(b) Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the Applicable Time (as defined below) and as
of the Time of Purchase and any Additional Time of Purchase, as the case may be, none of (i) any General Use Free Writing Prospectus
(as defined below) issued at or prior to the Applicable Time, and the Pricing Prospectus (as defined below), all considered together
(collectively, the &ldquo;<B>General Disclosure Package</B>&rdquo;), (ii) any individual Limited Use Free Writing Prospectus (as defined
below) issued at or prior to the Time of Purchase and any Additional Time of Purchase, as the case may be, or (iii) the bona fide electronic
road show, if any (as defined in Rule 433(h)(5) of the Rules and Regulations), that has been made available without restriction to any
person, when considered together with the General Disclosure Package, included or will include any untrue statement of a material fact
or omitted, or as of the Time of Purchase and any Additional Time of Purchase, as the case may be, will omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <I>provided</I>,
<I>however</I>, that the Company makes no representations or warranties as to information contained in or omitted from the General Disclosure
Package, any individual Limited Use Free Writing Prospectus or the bona fide electronic road show, if any, in reliance upon, and in conformity
with, written information furnished to the Company by or on behalf of the Underwriters specifically for inclusion therein, which information
the parties hereto agree is limited to the &ldquo;<B>Underwriter&rsquo;s Information</B>&rdquo; which is defined as the information set
forth in <U>Section 15</U>. As used in this <U>Section 2(b)</U> and elsewhere in this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Applicable
Time</B>&rdquo; means 4:30 P.M., Eastern Standard Time, on the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>General
Use Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus identified on <U>Schedule C</U> to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Issuer
Free Writing Prospectus</B>&rdquo; means any &ldquo;<B>issuer free writing prospectus</B>,&rdquo; as defined in Rule 433 of the Rules
and Regulations relating to the Notes in the form filed or required to be filed with the Commission or, if not required to be filed,
in the form retained in the Company&rsquo;s records pursuant to Rule 433(g) of the Rules and Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Limited
Use Free Writing Prospectuses</B>&rdquo; means any Issuer Free Writing Prospectus that is not a General Use Free Writing Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Pricing
Prospectus</B>&rdquo; means the Base Prospectus as amended and supplemented immediately prior to the Applicable Time, including any document
incorporated by reference therein and any prospectus supplement deemed to be a part thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No order preventing or suspending the use of any Issuer
Free Writing Prospectus or the Prospectus relating to the Offering has been issued by the Commission, and no proceeding for that purpose
or pursuant to Section 8A of the Securities Act has been instituted or, to the knowledge of the Company, is threatened by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the time the Registration Statement became effective,
at the Applicable Time and at the Time of Purchase and any Additional Time of Purchase, as the case may be, the Registration Statement
conformed and will conform in all material respects to the requirements of the Securities Act and the Rules and Regulations and did not
and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
to make the statements therein not misleading; the Prospectus, at the time the Prospectus became effective and at the Time of Purchase
and any Additional Time of Purchase, as the case may be, conformed and will conform in all material respects to the requirements of the
Securities Act and the Rules and Regulations and did not and will not contain an untrue statement of a material fact or omit to state
a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading;
<I>provided</I>, <I>however</I>, that the foregoing representations and warranties in this <U>Section 2(d)</U> shall not apply to information
contained in or omitted from the Registration Statement or the Prospectus in reliance upon, and in conformity with, the Underwriter&rsquo;s
Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Issuer Free Writing Prospectus, if any, as of its
issue date and at all subsequent times through the completion of the public offer and sale of the Notes or until any earlier date that
the Company notified or notifies the Representative as described in <U>Section 4(c)</U>, did not, does not and will not include any information
that conflicted, conflicts or will conflict with the information contained in the Registration Statement, Pricing Prospectus or the Prospectus,
including any document incorporated by reference therein and any prospectus supplement deemed to be a part thereof that has not been
superseded or modified, or includes an untrue statement of a material fact or omitted or would omit to state a material fact required
to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made,
not misleading. The foregoing sentence does not apply to statements in or omissions from any Issuer Free Writing Prospectus in reliance
upon, and in conformity with, the Underwriter&rsquo;s Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The documents incorporated by reference in the Prospectus,
when they became effective or were filed with the Commission, as the case may be, conformed in all material respects to the requirements
of the Securities Act or the Exchange Act, as applicable, the Rules and Regulations and the rules and regulations of the Commission under
the Exchange Act, and none of such documents contained any untrue statement of a material fact or omitted to state any material fact
required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made,
not misleading; and any further documents so filed and incorporated by reference in the Prospectus, when such documents become effective
or are filed with the Commission, as the case may be, will conform in all material respects to the requirements of the Securities Act
or the Exchange Act, as applicable, the Rules and Regulations and the rules and regulations of the Commission under the Exchange Act
and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
to make the statements therein, in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(g)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is not an &ldquo;ineligible issuer&rdquo;
in connection with the Offering pursuant to Rules 164, 405 and 433 under the Securities Act. The Company has not, directly or indirectly,
distributed and will not distribute any offering material in connection with the Offering other than the Registration Statement, the
Pricing Prospectus, the Prospectus, any General Use Free Writing Prospectuses and any Limited Use Free Writing Prospectuses reviewed
and consented to by the Representative (which consent shall not be unreasonably withheld). The Company will file with the Commission
all Issuer Free Writing Prospectuses (other than a &ldquo;road show,&rdquo; as defined in Rule 433(d)(8) of the Rules and Regulations),
if any, in the time and manner required under Rules 163(b)(2) and 433(d) of the Rules and Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(h)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each of the Company and its Subsidiaries has been duly
organized and is validly existing as a corporation or other legal entity in good standing (or the foreign equivalent thereof) under the
laws of its jurisdiction of incorporation or organization. Each of the Company and its Subsidiaries is duly qualified to do business
and is in good standing as a foreign corporation or other legal entity in each jurisdiction in which its ownership or lease of its properties
or the conduct of its business requires such qualification and has all power and authority (corporate or other) necessary to own or hold
its properties and to conduct the businesses in which each is engaged, except where the failure to so qualify or have such power or authority
would not (i) have, singularly or in the aggregate, a material adverse effect on the condition (financial or otherwise), results of operations,
assets, or business of the Company and its Subsidiaries, taken as a whole, or (ii) impair in any material respect the ability of the
Company to perform its obligations under this Agreement or to consummate any transactions contemplated by this Agreement, the General
Disclosure Package, or the Prospectus (any such effect as described in clauses (i) or (ii), a &ldquo;<B>Material Adverse Effect</B>&rdquo;).
&ldquo;<B>Subsidiary</B>&rdquo; means any subsidiary of the Company as defined in Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has the full right, power and authority
to execute and deliver, and perform its obligations under, this Agreement, the Indenture, the Notes and the DTC Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(j)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Agreement has been duly authorized, executed and
delivered by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(k)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Indenture has been duly authorized by the Company
and, as of the Closing Date, will be duly executed and delivered by the Company and, assuming it has been executed and delivered by the
Trustee, will constitute a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms,
except as the enforcement thereof may be subject to (i) applicable bankruptcy, insolvency, reorganization, moratorium or other similar
laws now or thereafter in effect relating to creditors&rsquo; rights generally and (ii) general principles of equity (regardless of whether
enforcement is considered in a proceeding in equity or law).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(l)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The DTC Agreement has been duly authorized, executed
and delivered by the Company and is a valid and binding obligation of the Company, enforceable against the Company in accordance with
its terms, except as the enforcement thereof may be subject to (i) applicable bankruptcy, insolvency, reorganization, moratorium or other
similar laws now or thereafter in effect relating to creditors&rsquo; rights generally and (ii) general principles of equity (regardless
of whether enforcement is considered in a proceeding in equity or law).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(m)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Notes have been duly authorized for sale to the
Underwriters pursuant to this Agreement and, when executed and delivered by the Company and authenticated by the Trustee pursuant to
the provisions of this Agreement and of the Indenture relating thereto, against payment of the consideration set forth in this Agreement,
will be valid and legally binding obligations of the Company enforceable in accordance with their terms, subject to (i) applicable bankruptcy,
insolvency, reorganization, moratorium or other similar laws now or thereafter in effect relating to creditors&rsquo; rights generally
and (ii) general principles of equity (regardless of whether enforcement is considered in a proceeding in equity or law), and will be
entitled to the benefits of the Indenture relating thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(n)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Notes and the Indenture conform in all material
respects to the statements relating thereto contained in the General Disclosure Package and the Prospectus; and other than as contemplated
in the General Disclosure Package and the Prospectus, none of the Company or any of its Subsidiaries has issued any debt securities or
entered into any agreement or arrangement relating to the issuance of any debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(o)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All issued and outstanding shares of capital stock of
the Company outstanding prior to the issuance of the Firm Notes have been duly authorized and are validly issued, fully paid and non-assessable
and were issued in compliance in all material respects with United States federal and applicable state securities laws. All of the Company&rsquo;s
options, warrants and other rights to purchase or exchange any securities for shares of the Company&rsquo;s capital stock have been duly
authorized and validly issued and were issued in compliance in all material respects with United States federal and applicable state
securities laws. None of the outstanding shares of capital stock was issued in violation of any preemptive rights, rights of first refusal
or other similar rights to subscribe for or purchase securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(p)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The membership interests, capital stock, partnership
interests or other similar equity interests, as applicable, of each Subsidiary, have been duly authorized and validly issued, are fully
paid and nonassessable and, except to the extent set forth in the General Disclosure Package, are owned by the Company directly, free
and clear of any claim, lien, encumbrance, security interest, restriction upon voting or transfer or any other claim of any third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(q)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None of (1) the execution, delivery and performance
of this Agreement and the Indenture by the Company and (2) the issuance and sale of the Notes by the Company (with or without notice
or lapse of time or both) (x) conflicts with or results in a breach or violation of any of the terms or provisions of, constitutes a
default under, gives rise to any right of termination or other right or the cancellation or acceleration of any right or obligation or
loss of a benefit under or pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which
the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound or to which any of the
property or assets of the Company or any of its Subsidiaries is subject, (y) results in any violation of the provisions of the certificate
of incorporation or bylaws (or analogous governing instruments, as applicable) of the Company or any of its Subsidiaries, or (z) results
in any violation of provisions of any law, statute, rule, regulation, judgment, order or decree of any court or governmental agency or
body, domestic or foreign, having jurisdiction over the Company or any of its Subsidiaries or any of their properties or assets; except,
with respect to clauses (x) or (z), any contravention which would not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(r)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No consent, approval, authorization or order of, or
qualification with, any governmental body or agency or self-regulatory authority is required for the performance by the Company of its
obligations under this Agreement, the Indenture, the DTC Agreement and the Notes, except as have been obtained or as may be required
by (1) the securities or Blue Sky laws of the various states, (2) the bylaws, rules and regulations of FINRA or the Nasdaq Global Market
(&ldquo;<B>Nasdaq</B>&rdquo;) or (3) any necessary qualification under the Trust Indenture Act, in connection with the offer and sale
of the Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(s)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KMJ Corbin &amp; Company LLP, who has audited certain
financial statements of the Company and related schedules included or incorporated by reference in the Registration Statement, the General
Disclosure Package and the Prospectus, is an independent registered public accounting firm with respect to the Company as required by
the Securities Act and the Rules and Regulations and the Public Company Accounting Oversight Board (United States). To the knowledge
of the Company, except as pre-approved in accordance with the requirements set forth in Section 10A of the Exchange Act, the applicable
independent registered public accounting firms above have not been engaged by the Company or any of its Subsidiaries, as applicable,
to perform any &ldquo;prohibited activities&rdquo; (as defined in Section 10A of the Exchange Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(t)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and its Subsidiaries do not have any material
liabilities or obligations, direct or contingent (including any off-balance sheet obligations or any &ldquo;variable interest entities&rdquo;
within the meaning of the Financial Accounting Standards Board&rsquo;s Accounting Standards Codification Topic 810), which are not disclosed
in the General Disclosure Package, the Prospectus and the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(u)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since the date of the most recent financial statements
of the Company included or incorporated by reference in the Registration Statement, the General Disclosure Package or the Prospectus,
(i) there has not occurred any event or circumstance that has had or would reasonably be expected to have, individually or in the aggregate,
a Material Adverse Effect and (ii) each of the Company and its Subsidiaries, considered as one entity, has not incurred any material
liability or obligation, indirect, direct or contingent, not in the ordinary course of business nor entered into any material transaction
or agreement not in the ordinary course of business, in each case, other than is set forth or contemplated therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(v)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is no legal or governmental proceeding, action,
suit or claim pending or, to the Company&rsquo;s knowledge, threatened, to which the Company or any of its Subsidiaries is a party, or
to which any of the properties or assets of the Company or any of its Subsidiaries is subject, (i) other than proceedings accurately
described in all material respects in the General Disclosure Package or proceedings that would not have a Material Adverse Effect, or
(ii) that are required to be described in the Registration Statement, the General Disclosure Package or the Prospectus and are not so
described; and there are no statutes, regulations, contracts or other documents to which the Company or any of its Subsidiaries is subject
or by which the Company or any of its Subsidiaries is bound that are required to be described in the Registration Statement, the General
Disclosure Package or the Prospectus or to be filed as exhibits to the Registration Statement that are not described or filed as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(w)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither the Company nor any of its Subsidiaries is or,
after giving effect to the Offering and the application of the proceeds thereof as described in the General Disclosure Package and the
Prospectus, will become an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended, and
the rules and regulations of the Commission thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(x)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except to the extent expressly set forth in the General
Disclosure Package as part of the offering contemplated hereby, neither the Company, its Subsidiaries nor any of the Company&rsquo;s
or its Subsidiaries&rsquo; officers, directors or affiliates has bid for or purchased, for any account in which it or any of its affiliated
purchasers has a beneficial interest, any Notes, or attempted to induce any person to purchase any Notes; and has not, and has not caused
its affiliated purchasers to, make bids or purchase for the purpose of creating actual, or apparent, active trading in or of raising
the price of the Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(y)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and its Subsidiaries have good and marketable
title to all real and personal property owned by them which is material to the business of the Company and its Subsidiaries, taken as
a whole, in each case free and clear of all liens, encumbrances and defects of title except such as are described in the General Disclosure
Package or would not individually or in the aggregate have a Material Adverse Effect; and any real property and buildings held under
lease by the Company and its Subsidiaries are held by them under valid, subsisting and enforceable leases except such as are described
in the General Disclosure Package or would not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(z)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as disclosed in the General Disclosure Package,
neither the Company nor any of its Subsidiaries is in violation of any statute, rule, regulation, decision or order of any governmental
agency or body or any court, relating to the use, disposal or release of hazardous or toxic substances or relating to the protection
or restoration of the environment or human exposure to hazardous or toxic substances (collectively, &ldquo;<B>Environmental Laws</B>&rdquo;),
operates any real property contaminated with any substance that is subject to any Environmental Laws, is liable for any off-site disposal
or contamination pursuant to any Environmental Laws, or is subject to any claim relating to any Environmental Laws, which violation,
contamination, liability or claim would individually or in the aggregate have a Material Adverse Effect; and the Company is not aware
of any pending investigation which might lead to such a claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(aa)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as disclosed in the General Disclosure Package,
the Company and the Subsidiaries own or possess or can acquire on reasonable terms enforceable rights to use all patents, patent applications,
trademarks (both registered and unregistered), service marks, trade names, trademark registrations, service mark registrations, copyrights,
licenses and know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems
or procedures) (collectively, the &ldquo;<U>Intellectual Property</U>&rdquo;), necessary for the conduct of their respective businesses
as conducted as of the date hereof, except to the extent that the failure to own or possess or acquire adequate rights to use such Intellectual
Property would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; the Company and the Subsidiaries
have not received any written notice of any claim of infringement or conflict which asserted Intellectual Property rights of others,
which infringement or conflict, if the subject of an unfavorable decision, would result in a Material Adverse Effect; there are no pending,
or to the Company&rsquo;s knowledge, threatened judicial proceedings or interference proceedings against the Company or its Subsidiaries
challenging the Company&rsquo;s or any of its Subsidiary&rsquo;s rights in or to or the validity of the scope of any of the Company&rsquo;s
or any Subsidiary&rsquo;s patents, patent applications or proprietary information, except such proceedings that have been disclosed in
writing to the Representative or would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect;
no other entity or individual has any right or claim in any of the Company&rsquo;s or any of its Subsidiary&rsquo;s patents, patent applications
or any patent to be issued therefrom by virtue of any contract, license or other agreement entered into between such entity or individual
and the Company or any Subsidiary or by any non-contractual obligation, other than by written licenses granted by the Company or any
Subsidiary except for such right or claim that would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect; the Company and the Subsidiaries have not received any written notice of any claim challenging the rights of the Company
or its Subsidiaries in or to any Intellectual Property owned, licensed or optioned by the Company or any Subsidiary which claim, if the
subject of an unfavorable decision would reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(bb)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and the Subsidiaries: (A) are and at all
times have been in material compliance with all applicable Health Care Laws (as defined below) relating to the ownership, testing, development,
manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export
or disposal of any product under development, manufactured, marketed, sold or distributed by the Company or the Subsidiaries, (B) have
not received any Form 483 from the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;), written notice of adverse finding, warning
letter, or other written correspondence or notice from the FDA, the European Medicines Agency (the &ldquo;<B>EMA</B>&rdquo;), or any
other federal, state, local or foreign governmental or regulatory authority (each, a &ldquo;<U>Regulatory Authority</U>&rdquo;) alleging
or asserting noncompliance with any Health Care Laws or any licenses, certificates, approvals, clearances, authorizations, permits and
supplements or amendments thereto required by any such Applicable Laws (&ldquo;<B>Authorizations</B>&rdquo;), which would, individually
or in the aggregate, result in a Material Adverse Effect, (C) possess all Authorizations material to the Company and such Authorizations
are valid and in full force and effect and neither the Company nor the Subsidiaries is in violation of any term of any such Authorizations;
(D) have not received written notice of any material claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration
or other action from any Regulatory Authority or third party alleging that any Company product, operation or activity is in violation
of any applicable Health Care Laws or Authorizations and has no knowledge that any Regulatory Authority or third party is considering
any such claim, litigation, arbitration, action, suit, investigation or proceeding against the Company; (E) have not received written
notice that any Regulatory Authority has taken, is taking or, to the knowledge of the Company, intends to take action to limit, suspend,
modify or revoke any Authorizations material to the Company and has no knowledge that any Regulatory Authority is considering such action;
(F) have filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments as required by any applicable Health Care Laws or Authorizations, except where the failure to file such
reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments would not result in a Material
Adverse Effect, and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments
were complete and correct on the date filed (or were corrected or supplemented by a subsequent submission); and (G) have not initiated
any recalls, field notifications, field corrections, market withdrawals or replacements, warnings, &ldquo;dear doctor&rdquo; letters,
investigator notices, safety alerts or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance
of any product marketed by the Company or any Subsidiary. For purposes of this Agreement, &ldquo;<B>Health Care Laws</B>&rdquo; means:
(i) the Federal Food, Drug, and Cosmetic Act and the regulations promulgated thereunder; (ii) all applicable federal, state, local and
all applicable foreign health care related fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C.
Section 1320a-7b(b)), the U.S. Physician Payment Sunshine Act (42 U.S.C. &sect; 1320a-7h), the U.S. Civil False Claims Act (31 U.S.C.
Section 3729 et seq.), the criminal False Claims Law (42 U.S.C. &sect; 1320a-7b(a)), all criminal laws relating to health care fraud
and abuse, including but not limited to 18 U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under the U.S.
Health Insurance Portability and Accountability Act of 1996 (&ldquo;HIPAA&rdquo;) (42 U.S.C. Section 1320d et seq.), the exclusion laws
(42 U.S.C. &sect; 1320a-7), the civil monetary penalties law (42 U.S.C. &sect; 1320a-7a), the statutes, regulations and directives of
applicable government funded or sponsored healthcare programs, and the regulations promulgated pursuant to such statutes; (iii) HIPAA,
as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.), and the regulations
promulgated thereunder and any state or non-U.S. counterpart thereof or other law or regulation the purpose of which is to protect the
privacy of individuals or prescribers; (iv) Medicare (Title XVIII of the Social Security Act); (v) Medicaid (Title XIX of the Social
Security Act); and (vi) any and all other applicable health care laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(cc)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All animal and other preclinical studies and clinical
trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company&rsquo;s knowledge, being
conducted in all material respects in compliance with all applicable Health Care Laws and in accordance with experimental protocols,
procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as
applied to comparable products to those being developed by the Company applicable, except where such noncompliance would not reasonably
be expected to have a Material Adverse Effect; the descriptions of the results of such preclinical studies and clinical trials contained
in the Registration Statement, the General Disclosure Package and the Prospectus are accurate in all material respects, and the Company
has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical
trial or preclinical study results described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus
when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence
from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination or suspension of any preclinical
studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement, the General Disclosure
Package and the Prospectus or the results of which are referred to in the Registration Statement, the General Disclosure Package and
the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(dd)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has established and administers a compliance
program applicable to the Company, to assist the Company and the directors, officers and employees of the Company in complying with applicable
regulatory guidelines (including, without limitation, those administered by the FDA, the EMA, and any other foreign, federal, state or
local governmental or regulatory authority having jurisdiction over the Company and performing functions similar to those performed by
the FDA or EMA); except where such noncompliance would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ee)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each of the Company and its Subsidiaries maintains a
system of internal accounting and other controls (A) sufficient to provide reasonable assurances that (i) transactions are executed in
accordance with management&rsquo;s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation
of financial statements in conformity with GAAP and to maintain accountability for assets; (iii) access to assets is permitted only in
accordance with management&rsquo;s general or specific authorization; and (iv) the recorded accountability for assets is compared with
existing assets at reasonable intervals and appropriate action is taken with respect to any differences and (B) which are effective in
all material respects to perform the functions for which they were established. Except as described in the General Disclosure Package,
since the end of the Company&rsquo;s most recent audited fiscal year, there has been (A) no material weakness or significant deficiencies
in the Company&rsquo;s internal control over financial reporting (whether or not remediated), (B) no change in the Company&rsquo;s internal
control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal
control over financial reporting, and (C) no fraud, whether or not material, that involves management or other employees who have a significant
role in the Company&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ff)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No relationship, direct or indirect, exists between
or among the Company and any of its Subsidiaries, on the one hand, and the directors, officers, stockholders (or analogous interest holders),
customers or suppliers of the Company or any of its Subsidiaries or any of their affiliates, on the other hand, which is required to
be described in the General Disclosure Package or the Prospectus or a document incorporated by reference therein and which is not so
described.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(gg)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither the Company nor any of its Subsidiaries, nor,
to the knowledge of the Company, any of its directors, officers, agents, employees, affiliates or other person acting on their behalf
is aware of or has taken any action, directly or indirectly, that has violated or would result in a violation by such persons of the
Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the &ldquo;<B>FCPA</B>&rdquo;), including,
without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer,
payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the
giving of anything of value to any &ldquo;foreign official&rdquo; (as such term is defined in the FCPA) or any foreign political party
or official thereof or any candidate for foreign political office, in contravention of the FCPA. The Company and its Subsidiaries have
instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued
compliance therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(hh)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The operations of the Company and its Subsidiaries are
and have been conducted at all times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency
and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules
and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by
any governmental agency (collectively, the &ldquo;<B>Money Laundering Laws</B>&rdquo;) and no action, suit or proceeding by or before
any court or governmental agency, authority or body or any arbitrator involving the Company or any of its Subsidiaries with respect to
the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ii)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither the Company nor any of its Subsidiaries is currently
subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<B>OFAC</B>&rdquo;);
and the Company will not directly or indirectly use the proceeds of this Offering, or lend, contribute or otherwise make available such
proceeds to any Subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person
currently subject to any U.S. sanctions administered by OFAC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(jj)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No person or entity has the right to require registration
of any securities of the Company or any of its Subsidiaries under the Securities Act because of the filing or effectiveness of the Registration
Statement, except as set forth therein or in the General Disclosure Package.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(kk)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither the Company nor any of its Subsidiaries is a
party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against
the Company or the Underwriters for a brokerage commission, finder&rsquo;s fee or like payment in connection with the Offering or any
transaction contemplated by this Agreement, the Registration Statement, the General Disclosure Package or the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ll)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No forward-looking statement (within the meaning of
Section 27A of the Securities Act and Section 21E of the Exchange Act) contained in either the General Disclosure Package or the Prospectus
has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(mm)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to, and in compliance in all
material respects with, the reporting requirements of Section 13 or Section 15(d) of the Exchange Act. As of the filing date of the Registration
Statement and as of any update of the Registration Statement pursuant to Section 10(a)(3) of the Securities Act (including the filing
of any Annual Report on Form 10-K), the Company was eligible to file a &ldquo;shelf&rdquo; Registration Statement on Form S-3 with the
Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(nn)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is in compliance in all material respects
with all applicable provisions of the Sarbanes-Oxley Act of 2002 and all applicable rules and regulations promulgated thereunder or is
implementing the provisions thereof that are currently in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(oo)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The statistical and market-related data included in
the General Disclosure Package are based on or derived from sources that the Company believes to be reliable and accurate, and such data
agree with the sources from which they are derived.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(pp)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as otherwise disclosed in the General Disclosure
Package, each of the Company and its Subsidiaries possesses such valid and current material certificates, authorizations or permits issued
by the appropriate state, federal or foreign regulatory agencies or bodies necessary to conduct their respective businesses, and neither
the Company nor any Subsidiary of the Company has received, or has any reason to believe that it will receive, any notice of proceedings
relating to the revocation or modification of, or non-compliance with, any such certificate, authorization or permit which, individually
or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to result in a Material
Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(qq)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each of the Company and its Subsidiaries has filed all
material federal, state and foreign income and franchise tax returns or have properly requested extensions thereof and have paid all
material taxes required to be paid by any of them and, if due and payable, any related or similar assessment, fine or penalty levied
against any of them except as may be being contested in good faith and by appropriate proceedings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(rr)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as set forth in the General Disclosure Package,
neither the Company nor any Subsidiary directly or indirectly controls, is controlled by, or is under common control with, or is an associated
person (within the meaning of Article I, Section 1(ee) of the By-laws of FINRA) of, any member firm of FINRA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ss)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No approval of the stockholders of the Company under
the rules and regulations of Nasdaq (including Nasdaq Listing Rule 5635) is required for the Company to issue and deliver the Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(tt)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as described in the General Disclosure Package,
the Company has not sold, issued or distributed any securities of the Company during the six-month period preceding the date hereof,
including any sales pursuant to Rule 144A under, or Regulation D or S of, the Securities Act, other than shares of Common Stock issued
pursuant to employee benefit plans, qualified equity compensation plans or other employee compensation plans or pursuant to outstanding
options, rights or warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(uu)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as otherwise disclosed in the General Disclosure
Package, each of the Company and its Subsidiaries maintains insurance issued by nationally recognized insurers covering their respective
properties, operations, personnel and businesses, with policies in such amounts and with such deductibles and covering such risks as
the Company reasonably deems adequate. The Company has no reason to believe that it or any of its Subsidiaries will not be able (i) to
renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions
as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(vv)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company nor, to the Company&rsquo;s knowledge, any
of its directors, officers or affiliates has not taken, directly or indirectly, any action designed to or that might be reasonably expected
to cause or result in stabilization or manipulation of the price of any &ldquo;reference security&rdquo; (as defined in Rule 100 of Regulation
M under the 1934 Act (&ldquo;<B>Regulation M</B>&rdquo;)), whether to facilitate the sale or resale of the Notes or otherwise, and has
taken no action which would directly or indirectly violate Regulation M.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(ww)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has not distributed and will not distribute,
prior to the later of (i) the expiration or termination of the option granted to the Underwriters in <U>Section 1</U> and (ii) the completion
of distribution of the Notes, any offering material in connection with the offering and sale of the Notes other than a preliminary prospectus,
the Pricing Prospectus, the Prospectus, any free writing prospectus reviewed and consented to by the Representative, or the Registration
Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(xx)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any certificate signed by or on behalf of the Company
and delivered to the Representative or to counsel for the Underwriters shall be deemed to be a representation and warranty by the Company
to the Underwriters as to the matters covered thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>3.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>The Closing</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of the purchase price for the Firm Notes shall
be made to the Company by Federal Funds wire transfer against delivery of such Firm Notes to or as designated by the Representative through
the facilities of DTC for the respective accounts of the Underwriters. Such payment and delivery shall be made at 10:00 A.M., Eastern
Standard Time, on June 17, 2021 (such date, the &ldquo;<B>Closing Date</B>&rdquo;). The time at which such payment and delivery are to
be made is hereinafter sometimes called the &ldquo;<B>Time of Purchase</B>.&rdquo; Electronic transfer of the Firm Notes shall be made
at the Time of Purchase in such names and in such denominations as the Representative shall specify.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of the purchase price for the Additional Notes
shall be made at the Additional Time of Purchase in the same manner and at the same office and time of day as the payment for the Firm
Notes. Electronic transfer of the Additional Notes shall be made at the Additional Time of Purchase in such names and in such denominations
as the Representative shall specify.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery of the documents required to be delivered to
the Underwriters pursuant to <U>Sections 4</U> and <U>6</U> hereof shall be at 10:00 A.M., Eastern Standard Time, on June 17, 2021, on
the Closing Date or the Additional Closing Date, as the case may be, at the offices of Duane Morris LLP, 1540 Broadway, New York, New
York 10036.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>4.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Further Covenants and Agreements of the Company</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants and agrees with the Underwriters as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To prepare the Rule 462(b) Registration Statement, if
necessary, in a form approved by the Representative, and file such Rule 462(b) Registration Statement with the Commission on the date
hereof; to prepare the Prospectus in a form approved by the Representative, containing information previously omitted at the time of
effectiveness of the Registration Statement in reliance on rules 430A, 430B and 430C and to file such Prospectus pursuant to Rule 424(b)
of the Rules and Regulations not later than the second business day following the execution and delivery of this Agreement or, if applicable,
such earlier time as may be required by Rule 430A of the Rules and Regulations; to notify the Representative promptly of the Company&rsquo;s
intention to file or prepare any supplement or amendment to any Registration Statement or to the Prospectus in connection with this Offering
and to provide a draft of any such amendment or supplement to the Registration Statement, the General Disclosure Package or the Prospectus
to the Representative, for review within an amount of time that is reasonably practical under the circumstances and prior to filing,
and to file no such amendment or supplement to which the Representative shall have reasonably objected in writing; to advise the Representative,
promptly after it receives notice thereof, of the time when any amendment to any Registration Statement has been filed in connection
with the Offering or becomes effective or any supplement to the General Disclosure Package or the Prospectus or any amended Prospectus
has been filed and to furnish the Representative with copies thereof; to file within the time periods prescribed by the Exchange Act,
including any extension thereof, all material required to be filed by the Company with the Commission pursuant to Rule 433(d) or 163(b)(2),
as the case may be; to advise the Representative, promptly after it receives notice thereof, of the issuance by the Commission of any
stop order or of any order preventing or suspending the use of any Issuer Free Writing Prospectus or the Prospectus, of the suspension
of the qualification of the Notes for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding for any
such purpose, or of any request by the Commission for the amending or supplementing of the Registration Statement, the General Disclosure
Package or the Prospectus or for additional information; and, in the event of the issuance of any stop order or of any order preventing
or suspending the use of any Issuer Free Writing Prospectus or the Prospectus or suspending any such qualification, and promptly to use
its best efforts to obtain the withdrawal of such order.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To prepare a final term sheet for the Notes, containing
solely a description of final terms of the Notes and the offering thereof, in the form approved by you and attached as <U>Schedule D
</U>hereto and to file such term sheet pursuant to, and within the time required by, Rule 433(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That, unless it obtains the prior consent of the Representative,
it has not made and will not make any offer relating to the Notes that would constitute a &ldquo;free writing prospectus&rdquo; as defined
in Rule 405 of the Rules and Regulations unless the prior written consent of the Representative has been received (each, a &ldquo;<B>Permitted
Free Writing Prospectus</B>&rdquo;), other than a free writing prospectus containing the information contained in the final term sheet
prepared and filed pursuant to <U>Section 4(b)</U> hereof; provided that the prior written consent of the Representative shall be deemed
to have been given in respect of the Free Writing Prospectuses included in <U>Schedule C</U> hereto and any electronic road show, if
any. The Company shall furnish to the Representative, a reasonable amount of time prior to the proposed time of filing or use thereof,
a copy of each proposed free writing prospectus or any amendment or supplement thereto to be prepared by or on behalf of, used by, or
referred to by the Company. The Company represents that it has treated and agrees that it will treat each Permitted Free Writing Prospectus
as an Issuer Free Writing Prospectus, and that it has and will comply with the requirements of Rules 164 and 433 of the Rules and Regulations
applicable to any Issuer Free Writing Prospectus, including the requirements relating to timely filing with the Commission, legending
and record keeping.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If at any time when a Prospectus relating to the Notes
is required to be delivered under the Securities Act, any event occurs or condition exists as a result of which the Prospectus, as then
amended or supplemented, would include any untrue statement of a material fact or omit to state a material fact necessary in order to
make the statements therein, in light of the circumstances under which they were made, not misleading, or the Registration Statement,
as then amended or supplemented, would include any untrue statement of a material fact or omit to state a material fact necessary to
make the statements therein not misleading, or if for any other reason it is necessary at any time to amend or supplement any Registration
Statement or the Prospectus to comply with the Securities Act or the Exchange Act, the Company will promptly notify the Representative,
and upon the Representative&rsquo;s request, the Company will promptly prepare and file with the Commission, at the Company&rsquo;s expense,
an amendment to the Registration Statement or an amendment or supplement to the Prospectus that corrects such statement or omission or
effects such compliance. The Company consents to the use of the Prospectus or any amendment or supplement thereto by the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the extent not available on the Commission&rsquo;s
EDGAR system, to make generally available to its security holders as soon as practicable, but in any event not later than eighteen (18)
months after the effective date of each Registration Statement (as defined in Rule 158(c) of the Rules and Regulations), an earnings
statement of the Company and its consolidated Subsidiaries (which need not be audited) complying with Section 11(a) of the Securities
Act and the Rules and Regulations (including, at the option of the Company, Rule 158).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To take promptly from time to time such actions as the
Representative may reasonably request to qualify the Notes for offering and sale under the securities or Blue Sky laws of such jurisdictions
(domestic or foreign) as the Representative may designate and to continue such qualifications in effect, and to comply with such laws,
for so long as required to permit the offer and sale of Notes in such jurisdictions; <I>provided</I> that the Company and its Subsidiaries
shall not be obligated to qualify as foreign corporations in any jurisdiction in which they are not so qualified or to file a general
consent to service of process in any jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(g)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To supply the Underwriters with copies of all correspondence
to and from, and all documents issued to and by, the Commission in connection with the registration of the Notes under the Securities
Act or the Registration Statement or the Prospectus, or any amendment or supplement thereto or document incorporated by reference therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(h)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the Time of Purchase and the Additional Time
of Purchase, if any, not to issue any press release or other communication directly or indirectly or hold any press conference (other
than the Company&rsquo;s customary quarterly press release and conference call) without the prior written consent of the Representative
(which consent shall not be unreasonably withheld).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until the Representative shall have notified the Company
of the completion of the Offering, that the Company will not, and will cause its affiliated purchasers (as defined in Regulation M under
the Exchange Act) not to, either alone or with one or more other persons, and except to the extent expressly set forth in the General
Disclosure Package as part of the offering contemplated hereby, bid for or purchase, for any account in which it or any of its affiliated
purchasers has a beneficial interest, any Notes, or attempt to induce any person to purchase any Notes; and not to, and to cause its
affiliated purchasers not to, make bids or purchase for the purpose of creating actual, or apparent, active trading in or of raising
the price of the Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(j)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To apply the net proceeds from the sale of the Notes
as set forth in the Registration Statement, the General Disclosure Package and the Prospectus under the heading &ldquo;Use of Proceeds.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(k)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not to sell, offer to sell, contract or agree to sell,
hypothecate, pledge, grant any option to purchase or otherwise dispose of or agree to dispose of, directly or indirectly, any debt securities
issued or guaranteed by the Company or any securities convertible into or exchangeable or exercisable for debt securities issued or guaranteed
by the Company or file or cause to be declared effective a registration statement under the Securities Act with respect to any of the
foregoing for a period of 30 days after the date hereof without the prior written consent of the Representative, which may not be unreasonably
withheld. The foregoing sentence shall not apply to the registration of the Notes and the sales to the Underwriters pursuant to this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(l)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To cooperate with the Representative and use its commercially
reasonable efforts to permit the offered Securities to be eligible for clearance and settlement through the facilities of DTC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(m)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To use its reasonable best efforts to list, effect and
maintain, subject to notice of issuance, the Notes on Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(n)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until the Representative shall have notified the Company
of the completion of the offering of the Notes, the Company will not take directly or indirectly any action designed, or that might reasonably
be expected to cause or result in, or that will constitute, stabilization or manipulation of the price of any security of the Company
to facilitate the sale or resale of any of the Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(o)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To use its reasonable best efforts to do and perform
all things required to be done or performed under this Agreement by the Company prior to the Time of Purchase or the Additional Time
of Purchase, as applicable and to satisfy all conditions precedent to the delivery of the Notes to be delivered at such time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>5.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Payment of Expenses</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company agrees to pay, or reimburse if paid by the Underwriters, whether or not the transactions contemplated hereby are consummated
or this Agreement is terminated: (a) the costs incident to the authorization, issuance, sale and delivery of the Notes to the Underwriters
and any taxes payable in that connection; (b) the costs incident to the registration of the Notes under the Securities Act; (c) the costs
incident to the preparation, printing and distribution of the Registration Statement, the Base Prospectus, any Issuer Free Writing Prospectus,
the General Disclosure Package, the Prospectus, any amendments, supplements and exhibits thereto or any document incorporated by reference
therein; (d) the reasonable and documented fees and expenses of counsel to the Underwriters incurred in connection with securing any
required review by FINRA and any filings made with FINRA; (e) all costs and expenses incident to listing the Notes on Nasdaq; (f) the
fees and expenses of counsel for the Underwriters incurred in connection with qualifying the Notes under the securities laws of the several
jurisdictions as provided in <U>Section 4(e)</U> and of preparing, printing and distributing wrappers and blue sky memoranda; (g) the
fees and expenses of the Trustee and any transfer agent, registrar or depository with respect to the Notes; (h) the expenses and application
fees incurred in connection with the approval of the Notes for book-entry transfer by DTC; (i) the reasonable fees and disbursements
of counsel to the Underwriters in an aggregate amount not to exceed $50,000 and (j) all other costs and expenses of the Company incident
to the offering of the Notes by, or the performance of the obligations of, the Company under this Agreement (including, without limitation,
the fees and expenses of the Company&rsquo;s counsel and the Company&rsquo;s independent accountants and the travel and other reasonable
expenses incurred by Company personnel in connection with any &ldquo;road show&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>6.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conditions to the Obligations of the Underwriters,
and the Sale of the Notes</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. The obligations of the Underwriters
hereunder, and the closing of the sale of the Notes, are subject to the accuracy, when made and as of the Applicable Time and at the
Time of Purchase or the Additional Time of Purchase, as the case may be, of the representations and warranties of the Company contained
herein (except for inaccuracies that would not result in a Material Adverse Effect), to the accuracy of the statements of the Company
made in any certificates pursuant to the provisions hereof, to the performance by the Company, in all material respects, of its obligations
hereunder, and to each of the following additional terms and conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No stop order suspending the effectiveness of the Registration
Statement or any part thereof, preventing or suspending the use of the Base Prospectus, the Prospectus or any Permitted Free Writing
Prospectus or any part thereof shall have been issued and no proceedings for that purpose or pursuant to Section 8A under the Securities
Act shall have been initiated by the Commission, and all requests for additional information on the part of the Commission (to be included
or incorporated by reference in the Registration Statement or the Prospectus or otherwise) shall have been complied with; the Rule 462(b)
Registration Statement, if any, each Issuer Free Writing Prospectus, if any, and the Prospectus shall have been filed with the Commission
within the applicable time period prescribed for such filing by, and in compliance with, the Rules and Regulations and in accordance
with <U>Section 4(a)</U>, and the Rule 462(b) Registration Statement, if any, shall have become effective immediately upon its filing
with the Commission; and FINRA shall have raised no objection to the fairness and reasonableness of the terms of this Agreement or the
transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registration Statement or any amendment or supplement
thereto shall not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
to make the statements therein not misleading, and none of the General Disclosure Package, any Issuer Free Writing Prospectus or the
Prospectus, or any amendment or supplement thereto, shall contain an untrue statement of a material fact or omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances in which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall have furnished to the Representative
a certificate, dated the Closing Date or the Additional Closing Date, as the case may be, of its Chief Executive Officer and its Chief
Financial Officer stating that (i) since the effective date of the Registration Statement, no event has occurred which should have been
set forth in a supplement or amendment to the Registration Statement, the General Disclosure Package or the Prospectus, (ii) to the best
of their knowledge after reasonable investigation, as of such date, the representations and warranties of the Company in this Agreement
are true and correct, except for inaccuracies that would not result in a Material Adverse Effect, and the Company has complied, in all
material respects, with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to
such date, and (iii) there has not been, subsequent to the date of the most recent audited financial statements included or incorporated
by reference in the General Disclosure Package, any material adverse change in the financial position or results of operations of the
Company and its Subsidiaries, taken as a whole, or any change or development that, individually or in the aggregate, would reasonably
be expected to involve a material adverse change in or affecting the condition (financial or otherwise), results of operations, business
or assets of the Company and its Subsidiaries, taken as a whole, except as set forth in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since the date of the latest audited financial statements
with respect to the Company and its Subsidiaries included in the General Disclosure Package or incorporated by reference in the General
Disclosure Package as of the date hereof, (i) neither the Company nor any of its Subsidiaries shall have sustained any loss or interference
with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court
or governmental action, order or decree, otherwise than as set forth in the General Disclosure Package, and (ii) there shall not have
been any change in the capital stock of the Company or any change in the long-term debt of the Company and its Subsidiaries, taken as
a whole, or any change or any development in or affecting the business, general affairs, management, financial position, stockholders&rsquo;
equity or results of operations of the Company and its Subsidiaries, taken as a whole, otherwise than as set forth in the General Disclosure
Package, the effect of which, in any such case described in clause (i) or (ii) of this <U>Section 6(e)</U>, would result in a Material
Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No action shall have been taken and no law, statute,
rule, regulation or order shall have been enacted, adopted or issued by any governmental agency or body which would prevent the issuance
or sale of the Notes or result in a Material Adverse Effect; and no injunction, restraining order or order of any other nature by any
United States federal or state court of competent jurisdiction shall have been issued which would prevent the issuance or sale of the
Notes or result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to the execution and delivery of this Agreement
there shall not have occurred any of the following: (i) trading in securities generally on the New York Stock Exchange or the Nasdaq
Stock Market or in the over-the-counter market, or trading in any securities of the Company on any exchange or in the over-the-counter
market, shall have been suspended or materially limited, or minimum or maximum prices or maximum range for prices shall have been established
on any such exchange or such market by the Commission, by such exchange or market or by any other regulatory body or governmental authority
having jurisdiction; (ii) a banking moratorium shall have been declared by United States federal or state authorities or a material disruption
has occurred in commercial banking or securities settlement or clearance services in the United States; (iii) the United States shall
have become engaged in hostilities, or the subject of an act of terrorism, or there shall have been an outbreak of or escalation in hostilities
involving the United States, or there shall have been a declaration of a national emergency or war by the United States; (iv) if there
has been, in the judgment of the Representative, since the time of execution of this Agreement or since the respective dates as of which
information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse change in
the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and its subsidiaries,
considered as one enterprise, whether or not arising in the ordinary course of business, or (iv) there shall have occurred such a material
adverse change in general economic, political or financial conditions (or the effect of international conditions on the financial markets
in the United States shall be such) as to make it, in the reasonable judgment of the Underwriter, impracticable or inadvisable to proceed
with the sale or delivery of the Notes on the terms and in the manner contemplated in the General Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(g)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Underwriters shall have received (i) an opinion
and negative assurance letter of Waller Lansden Dortch &amp; Davis, LLP, counsel for the Company, and (ii) Polsinelli PC, intellectual
property counsel for the Company, each dated the Closing Date or the Additional Closing Date, as the case may be, covering such matters
as the Underwriters shall reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(h)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Underwriters shall have received the favorable opinion
of Duane Morris LLP, counsel for the Underwriters, dated the Closing Date or the Additional Closing Date, as the case may be, and covering
such matters as the Underwriters shall reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(i)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Underwriters shall have received from KMJ Corbin
&amp; Company LLP letters dated, respectively, the date hereof, the Closing Date and, if applicable, the Additional Closing Date, in
form and substance satisfactory to the Representative containing statements and information of the type ordinarily included in accountants&rsquo;
&ldquo;comfort letters&rdquo; to underwriters with respect to the financial statements and certain financial information contained in
the General Disclosure Package, the Prospectus and the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(j)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall have furnished to the Representative
such further certificates and documents as the Representative may reasonably require for the purpose of enabling the Underwriters to
pass upon the issuance and sale of the Notes as herein contemplated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(k)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and the Trustee shall have executed and
delivered the First Supplemental Indenture and the Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any condition specified in this <U>Section 6</U> is not satisfied when and as required to be satisfied, this Agreement may be terminated
in the absolute discretion of the Representative by notice to the Company at any time on or prior to the Closing Date and, with respect
to the Additional Notes, at any time on or prior to the applicable Additional Closing Date, which termination shall be without liability
on the part of any party to any other party (except to the extent provided in <U>Section 8</U> hereof), except that <U>Sections 5</U>,
<U>6</U>, <U>8</U> and <U>9</U> shall at all times be effective and shall survive such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>7.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Increase in Underwriters&rsquo; Commitments</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to <U>Section 6</U> hereof, if any Underwriter shall default in its obligation to take up and pay for the Firm Notes to be purchased
by it hereunder (otherwise than for a failure of a condition set forth in <U>Section 6</U> hereof) and if the aggregate principal amount
of Firm Notes which all Underwriters so defaulting shall have agreed but failed to take up and pay for does not exceed 10% of the total
aggregate principal amount of Firm Notes, the non-defaulting Underwriters shall take up and pay for (in addition to the aggregate principal
amount of Firm Notes they are obligated to purchase pursuant to <U>Section 1</U> hereof) the aggregate principal amount of Firm Notes
agreed to be purchased by all such defaulting Underwriters, as hereinafter provided. Such Notes shall be taken up and paid for by such
non-defaulting Underwriters in such amount or amounts as the Representative may designate with the consent of each Underwriter so designated
or, in the event no such designation is made, such Notes shall be taken up and paid for by all non-defaulting Underwriters pro rata in
proportion to the aggregate principal amount of Firm Notes set opposite the names of such non-defaulting Underwriters in <U>Schedule
A.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
relieving any defaulting Underwriter from its obligations hereunder, the Company agrees with the non-defaulting Underwriters that it
will not sell any Firm Notes hereunder unless all of the Firm Notes are purchased by the Underwriters (or by substituted Underwriters
selected by the Representative with the approval of the Company or selected by the Company with the Representative&rsquo;s approval).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a new Underwriter is or Underwriters are substituted by the Representative or by the Company for a defaulting Underwriter or Underwriters
in accordance with the foregoing provision, the Company or the Representative shall have the right to postpone the time of purchase for
a period not exceeding five business days in order that any necessary changes in the General Disclosure Package and other documents that
may be effected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term Underwriter as used in this Agreement shall refer to and include any Underwriter substituted under this <U>Section 7</U> with like
effect as if such substituted Underwriter had originally been named in <U>Schedule A</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the aggregate principal amount of Firm Notes which the defaulting Underwriter or Underwriters agreed to purchase exceeds 10% of the total
aggregate principal amount of Firm Notes which all Underwriters agreed to purchase hereunder, and if neither the non-defaulting Underwriters
nor the Company shall make arrangements within the five business day-period stated above for the purchase of all the Firm Notes which
the defaulting Underwriter or Underwriters agreed to purchase hereunder, then this Agreement shall terminate without further act or deed
and without any liability on the part of the Company to any non-defaulting Underwriter (except as provided in <U>Section 8</U>) and without
any liability on the part of any non-defaulting Underwriter to the Company. Nothing in this paragraph, and no action taken hereunder,
shall relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>8.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Indemnification and Contribution</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company agrees to indemnify and hold harmless each
Underwriter, its respective affiliates and each of their respective directors, officers, members, employees, representatives and agents
and their respective affiliates, and each person, if any, who controls such Underwriter within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act (collectively the &ldquo;<B>Underwriter Indemnified Parties</B>,&rdquo; and each, an &ldquo;<B>Underwriter
Indemnified Party</B>&rdquo;) against any loss, claim, damage, expense or liability whatsoever (or any action, investigation or proceeding
in respect thereof), joint or several, to which such Underwriter Indemnified Party may become subject, under the Securities Act or otherwise,
insofar as such loss, claim, damage, expense, liability, action, investigation or proceeding arises out of or is based upon (A) any untrue
statement or alleged untrue statement of a material fact contained in any Issuer Free Writing Prospectus, any &ldquo;issuer information&rdquo;
filed or required to be filed pursuant to Rule 433(d) of the Rules and Regulations, any Registration Statement or the Prospectus, or
in any amendment or supplement thereto or document incorporated by reference therein, (B) the omission or alleged omission to state in
any Issuer Free Writing Prospectus, any &ldquo;issuer information&rdquo; filed or required to be filed pursuant to Rule 433(d) of the
Rules and Regulations, any Registration Statement or the Prospectus, or in any amendment or supplement thereto or document incorporated
by reference therein, a material fact required to be stated therein or necessary to make the statements therein not misleading, or (C)
any breach of the representations and warranties of the Company contained herein or failure of the Company to perform its obligations
hereunder or pursuant to any law, and shall reimburse the Underwriter Indemnified Party promptly upon demand for any legal fees or other
expenses reasonably incurred by such Underwriter Indemnified Party in connection with investigating, or preparing to defend, or defending
against, or appearing as a third party witness in respect of, or otherwise incurred in connection with, any such loss, claim, damage,
expense, liability, action, investigation or proceeding, as such fees and expenses are incurred; <I>provided</I>, <I>however</I>, that
the Company shall not be liable in any such case to the extent that any such loss, claim, damage, expense or liability arises out of
or is based upon an untrue statement or alleged untrue statement in, or omission or alleged omission from, any Registration Statement
or the Prospectus, or any such amendment or supplement thereto, or any Issuer Free Writing Prospectus made in reliance upon and in conformity
with written information concerning the Underwriters furnished to the Company by or on behalf of the Underwriters specifically for use
therein, which information the parties hereto agree is limited to the Underwriter&rsquo;s Information. This indemnity agreement is not
exclusive and will be in addition to any liability, which the Company may otherwise have and shall not limit any rights or remedies which
may otherwise be available at law or in equity to each Underwriter Indemnified Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Underwriter severally and not jointly agrees to
indemnify and hold harmless the Company and its directors, its officers who signed the Registration Statement and each person, if any,
who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively the &ldquo;<B>Company
Indemnified Parties</B>&rdquo; and each a &ldquo;<B>Company Indemnified Party</B>&rdquo;) against any loss, claim, damage, expense or
liability whatsoever (or any action, investigation or proceeding in respect thereof), joint or several, to which such Company Indemnified
Party may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage, expense, liability, action, investigation
or proceeding arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in any
Issuer Free Writing Prospectus, any &ldquo;issuer information&rdquo; filed or required to be filed pursuant to Rule 433(d) of the Rules
and Regulations, any Registration Statement or the Prospectus, or in any amendment or supplement thereto, or (ii) the omission or alleged
omission to state in any Issuer Free Writing Prospectus, any &ldquo;issuer information&rdquo; filed or required to be filed pursuant
to Rule 433(d) of the Rules and Regulations, any Registration Statement or the Prospectus, or in any amendment or supplement thereto,
a material fact required to be stated therein or necessary to make the statements therein not misleading, but in each case only to the
extent that the untrue statement or alleged untrue statement or omission or alleged omission was made in reliance upon and in conformity
with written information furnished to the Company by or on behalf of such Underwriter specifically for use therein, which information
the parties hereto agree is limited to the Underwriter&rsquo;s Information, and shall reimburse the Company Indemnified Parties for any
legal or other expenses reasonably incurred by such party in connection with investigating or preparing to defend or defending against
or appearing as third party witness in connection with any such loss, claim, damage, liability, action, investigation or proceeding,
as such fees and expenses are incurred. This indemnity agreement is not exclusive and will be in addition to any liability which such
Underwriter might otherwise have and shall not limit any rights or remedies which may otherwise be available under this Agreement, at
law or in equity to the Company Indemnified Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promptly after receipt by an indemnified party under
this Section 8 of notice of the commencement of any action, the indemnified party shall, if a claim in respect thereof is to be made
against an indemnifying party under this Section 8, notify such indemnifying party in writing of the commencement of that action; <I>provided</I>,
<I>however</I>, that the failure to notify the indemnifying party shall not relieve it from any liability which it may have under this
Section 8 except to the extent it has been materially prejudiced by such failure; and, <I>provided</I>, <I>further</I>, that the failure
to notify an indemnifying party shall not relieve it from any liability which it may have to an indemnified party otherwise than under
this Section 8. If any such action shall be brought against an indemnified party, and it shall notify the indemnifying party thereof,
the indemnifying party shall be entitled to participate therein and, to the extent that it wishes, jointly with any other similarly notified
indemnifying party, to assume the defense of such action with counsel reasonably satisfactory to the indemnified party (which counsel
shall not, except with the written consent of the indemnified party, be counsel to the indemnifying party). After notice from the indemnifying
party to the indemnified party of its election to assume the defense of such action and approval by the indemnified party of counsel
as set forth herein, except as provided herein, the indemnifying party shall not be liable to the indemnified party under Section 8 for
any legal or other expenses subsequently incurred by the indemnified party in connection with the defense of such action other than reasonable
costs of investigation; <I>provided</I>, <I>however</I>, that any indemnified party shall have the right to employ separate counsel in
any such action and to participate in the defense of such action but the fees and expenses of such counsel (other than reasonable costs
of investigation which shall remain the expense of the Company) shall be at the expense of such indemnified party unless (i) in the case
of an Underwriter Indemnified Party, the employment thereof has been specifically authorized in writing by the Company in the case of
a claim for indemnification under <U>Section 8(a)</U>, or (ii) such indemnified party shall have been advised by its counsel that there
may be one or more legal defenses available to it which are different from or additional to those available to the indemnifying party,
or (iii) the indemnifying party has failed to assume the defense of such action and employ counsel reasonably satisfactory to the indemnified
party within a reasonable period of time after notice of the commencement of the action or the indemnifying party does not diligently
defend the action after assumption of the defense, in which case, if such indemnified party notifies the indemnifying party in writing
that it elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to
assume the defense of (or, in the case of a failure to diligently defend the action after assumption of the defense, to continue to defend)
such action on behalf of such indemnified party and the indemnifying party shall be responsible for legal or other expenses subsequently
incurred by such indemnified party in connection with the defense of such action; <I>provided</I>, <I>however</I>, that the indemnifying
party shall not, in connection with any one such action or separate but substantially similar or related actions in the same jurisdiction
arising out of the same general allegations or circumstances, be liable for the reasonable fees and expenses of more than one separate
firm of attorneys at any time for all such indemnified parties (in addition to any local counsel), which firm shall be designated in
writing by the Underwriter if the indemnified parties under this Section 8 consist of any Underwriter Indemnified Party or by the Company
if the indemnified parties under this Section 8 consist of any Company Indemnified Parties. Subject to this Section 8(d), the amount
payable by an indemnifying party under Section 8 shall include, but not be limited to, (x) reasonable legal fees and expenses of counsel
to the indemnified party and any other expenses in investigating, or preparing to defend or defending against, or appearing as a third
party witness in respect of, or otherwise incurred in connection with, any action, investigation, proceeding or claim, and (y) all amounts
paid in settlement of any of the foregoing. No indemnifying party shall, without the prior written consent of the indemnified parties,
settle or compromise or consent to the entry of judgment with respect to any pending or threatened action or any claim whatsoever, in
respect of which indemnification or contribution could be sought under this Section 8 (whether or not the indemnified parties are actual
or potential parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified
party in form and substance reasonably satisfactory to such indemnified party from all liability arising out of such action or claim
and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified
party. Subject to the provisions of the following sentence, no indemnifying party shall be liable for settlement of any pending or threatened
action or any claim whatsoever that is effected without its written consent (which consent shall not be unreasonably withheld or delayed),
but if settled with its written consent, or if its consent has been unreasonably withheld or delayed, or if there be a judgment for the
plaintiff in any such matter, the indemnifying party agrees to indemnify and hold harmless any indemnified party from and against any
loss or liability by reason of such settlement or judgment. In addition, if at any time an indemnified party shall have requested that
an indemnifying party reimburse the indemnified party for reasonable fees and expenses of counsel, such indemnifying party agrees that
it shall be liable for any settlement of the nature contemplated herein effected without its written consent if (i) such settlement is
entered into more than forty-five (45) days after receipt by such indemnifying party of the request for reimbursement, (ii) such indemnifying
party shall have received notice of the terms of such settlement at least thirty (30) days prior to such settlement being entered into
and (iii) such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date
of such settlement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the indemnification provided for in this <U>Section
8</U> is unavailable or insufficient to hold harmless an indemnified party under <U>Section 8(a)</U> or <U>Section 8(b)</U>, then each
applicable indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount paid, payable or otherwise
incurred by such indemnified party as a result of such loss, claim, damage, expense or liability (or any action, investigation or proceeding
in respect thereof), as incurred, (i) in such proportion as shall be appropriate to reflect the relative benefits received by the Company
on the one hand and the Underwriters on the other hand from the Offering, or (ii) if the allocation provided by clause (i) of this <U>Section
8(d)</U> is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred
to in clause (i) of this <U>Section 8(d)</U> but also the relative fault of the Company on the one hand and each of the respective Underwriters
on the other with respect to the statements, omissions, acts or failures to act which resulted in such loss, claim, damage, expense or
liability (or any action, investigation or proceeding in respect thereof) as well as any other relevant equitable considerations. The
relative benefits received by the Company on the one hand and the Underwriters on the other hand with respect to such Offering shall
be deemed to be in the same proportion as the total net proceeds from the Offering pursuant to this Agreement (before deducting expenses)
received by the Company bear to the total compensation received by the Underwriter in connection with the Offering, in each case as set
forth in the table on the cover page of the Prospectus. The relative fault of the Company on the one hand and the Underwriters on the
other hand shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact
or the omission or alleged omission to state a material fact relates to information supplied by the Company on the one hand or the Underwriters
on the other hand, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent
such untrue statement, omission, act or failure to act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and the Underwriters agree that it would not be just and equitable if contributions pursuant to this <U>Section 8(d)</U> were
to be determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations
referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, damage, expense, liability, action,
investigation or proceeding referred to above in this <U>Section 8(d)</U> shall be deemed to include, for purposes of this <U>Section
8(d)</U>, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating, preparing to defend
or defending against or appearing as a third party witness in respect of, or otherwise incurred in connection with, any such loss, claim,
damage, expense, liability, action, investigation or proceeding. Notwithstanding the provisions of this <U>Section 8(d)</U>, no Underwriter
shall be required to contribute any amount in excess of the total compensation received by such Underwriter hereunder less the amount
of any damages which such Underwriter has otherwise paid or become liable to pay by reason of any untrue or alleged untrue statement,
omission or alleged omission, act or alleged act or failure to act or alleged failure to act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">No
person guilty of fraudulent misrepresentation (within the meaning of Section 10(f) of the Securities Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>9.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Absence of Fiduciary Relationship</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.
The Company acknowledges and agrees that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Underwriters&rsquo; responsibility to the Company
is solely contractual in nature, the Underwriters have been retained solely to act as underwriters in connection with the Offering and
no fiduciary, advisory or agency relationship between the Company and any Underwriter has been created in respect of any of the transactions
contemplated by this Agreement, irrespective of whether such Underwriter has advised or is advising the Company on other matters;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the price of the Notes set forth in this Agreement was
established by the Company following discussions and arms-length negotiations with the Underwriters, and the Company is capable of evaluating
and understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated by this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no Underwriter has advised, and no Underwriter is advising,
the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction with respect to
the transactions contemplated hereby;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company shall consult with its own advisors concerning
such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby,
and no Underwriter shall have any responsibility or liability to the Company with respect thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(e)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no Underwriter has or will be rendering an opinion to
the Company as to the fairness of the terms of the offering of the Notes;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(f)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it has been advised that each Underwriter, and its respective
affiliates, is engaged in a broad range of transactions which may involve interests that differ from those of the Company and no Underwriter
has an obligation to disclose such interests and transactions to the Company by virtue of any fiduciary, advisory or agency relationship;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(g)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it waives, to the fullest extent permitted by law, any
claims it may have against any Underwriter for breach of fiduciary duty or alleged breach of fiduciary duty and agrees that each Underwriter
shall not have any liability (whether direct or indirect) to the Company in respect of such a fiduciary duty claim or to any person asserting
a fiduciary duty claim on behalf of or in right of the Company, including stockholders, employees or creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>10.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Successors; Persons Entitled to Benefit of
Agreement</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. This Agreement shall inure to the benefit of and be
binding upon the Underwriters, the Company, and their respective successors and assigns. Nothing expressed or mentioned in this Agreement
is intended or shall be construed to give any person, other than the persons mentioned in the preceding sentence, any legal or equitable
right, remedy or claim under or in respect of this Agreement, or any provisions herein contained, this Agreement and all conditions and
provisions hereof being intended to be and being for the sole and exclusive benefit of such persons and for the benefit of no other person;
except that the representations, warranties, covenants, agreements and indemnities of the Company contained in this Agreement shall also
be for the benefit of the Underwriter Indemnified Parties, and the indemnity of the Underwriters shall be for benefit of the Company
Indemnified Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>11.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Survival of Indemnities, Representations,
Warranties, Etc</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">. The respective indemnities, covenants, agreements,
representations, warranties and other statements of the Company and the Underwriters, as set forth in this Agreement or made by them
respectively, pursuant to this Agreement, shall remain in full force and effect, regardless of any investigation made by or on behalf
of the Underwriters, the Company or any person controlling any of them and shall survive delivery of and payment for the Notes. Notwithstanding
any termination of this Agreement, the indemnity and contribution agreements contained in <U>Section 8</U> and the covenants, representations,
warranties set forth in this Agreement shall not terminate and shall remain in full force and effect at all times.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>12.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notices</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.
All statements, requests, notices and agreements hereunder shall be in writing, and:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if to the Underwriters, shall be delivered or sent by
mail, overnight courier or email to B. Riley Securities, Inc., 299 Park Avenue, 21<SUP>st</SUP> Floor, New York, New York 10171, Attention:
Syndicate Department, with a copy to Duane Morris LLP Attn: James T. Seery, 1540 Broadway, New York, New York 10036.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if to the Company, shall be delivered or sent by mail,
overnight courier or email to Harrow Health, Inc., Attention: Mark L. Baum, 102 Woodmont Blvd., Suite 610, Nashville, Tennessee 37205,
with a copy to Waller Lansden Dortch &amp; Davis, LLP Attn: James H. Nixon III, Nashville City Center, 511 Union Street, Suite 2700,
Nashville, Tennessee 37219.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>13.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Definition of Certain Terms</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.
For purposes of this Agreement &ldquo;<B>business day</B>&rdquo; means any day on which the Nasdaq Stock Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>14.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Governing Law</U>. This Agreement shall be
governed by and construed in accordance with the laws of the State of New York.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>15.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Underwriter&rsquo;s Information</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.
The parties hereto acknowledge and agree that, for all purposes of this Agreement, the Underwriter&rsquo;s Information consists solely
of the following information in the General Disclosure Package, the Prospectus and in the Registration Statement: the concession figure
appearing in the first paragraph under the section entitled &ldquo;Underwriting &ndash; Discounts and Expenses&rdquo; and the information
contained in the second and fourth paragraphs relating to stabilization transactions under the section entitled &ldquo;Underwriting &ndash;
Price Stabilization, Short Positions.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>16.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Partial Unenforceability</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.
The invalidity or unenforceability of any section, paragraph, clause or provision of this Agreement shall not affect the validity or
enforceability of any other section, paragraph, clause or provision hereof. If any section, paragraph, clause or provision of this Agreement
is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor
changes) as are necessary to make it valid and enforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>17.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>General</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.
This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous
oral agreements, understandings and negotiations with respect to the subject matter hereof. In this Agreement, the masculine, feminine
and neuter genders and the singular and the plural include one another. The section headings in this Agreement are for the convenience
of the parties only and will not affect the construction or interpretation of this Agreement. This Agreement may be amended or modified,
and the observance of any term of this Agreement may be waived, only by a writing signed by the Company and the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000"><B>18.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Counterparts</U></FONT></B><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.
This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures
thereto and hereto were upon the same instrument and such signatures may be delivered by facsimile.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
Page Follows</I>]<BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing correctly sets forth the understanding between the Company and the several Underwriters, please so indicate in the space
provided below for that purpose, whereupon this agreement and your acceptance shall constitute a binding agreement between the Company
and the Underwriters, severally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours, </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HARROW
    HEALTH, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Mark L. Baum </I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    L. Baum</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>B.
RILEY SECURITIES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
themselves and as Representative</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
the several Underwriters named</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
<U>Schedule A</U> hereto</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted
and agreed to as of the date first above written:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>B.
    RILEY SECURITIES, INC. </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Patrice McNicoll </I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrice
    McNicoll</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Head
    of Investment Banking</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><U>SCHEDULE
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Underwriters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Underwriters</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<BR> Principal<BR> Amount of<BR> Securities to<BR> be Purchased</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: left">B. Riley Securities, Inc.</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">14,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Ladenburg Thalmann &amp; Co. Inc.</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,500,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">17,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><U>SCHEDULE
B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pricing
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate principal amount of the Firm Notes is $17,500,000 (representing 700,000 Notes).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public offering price for the Notes shall be $25.75.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gross proceeds for the Notes shall be $18,025,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase price for the Notes to be paid by the several Underwriters shall be 96.0% of the public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interest rate is 8.625%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
maturity date for the Notes shall be April 30, 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to February 1, 2026, the Company may, at its option, redeem the Notes, in whole at any time or in part from time to time, at a redemption
price equal to 100% of the principal amount of the Notes to be redeemed, plus a Make-Whole Amount (as defined in the Prospectus Supplement),
if any, plus accrued and unpaid interest to, but excluding, the date of redemption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may redeem the Notes for cash in whole or in part at any time at its option on or after February 1, 2026 and prior to maturity,
at a price equal to 100% of their principal amount, plus accrued and unpaid interest to, but excluding, the date of redemption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULE
C</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Free
Writing Prospectuses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Final
term sheet as prepared pursuant to <U>Section 4(b)</U> hereto and filed as an Issuer Free Writing Prospectus by the Company with the
Commission on June 14, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULE
D</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
pursuant to Rule 433</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333- 239669</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuer
Free Writing Prospectus </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Supplementing
the Preliminary Prospectus Supplement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>dated
June 14, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HARROW
HEALTH, INC.<BR>
US $18,025,000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.625%
Senior Notes Due 2026<BR>
Final Term Sheet</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>June
14, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
pricing term sheet is qualified in its entirety by reference to the Preliminary Prospectus Supplement, dated June 14, 2021 (the
&ldquo;Preliminary Prospectus Supplement&rdquo;). The information in this pricing term sheet supplements the Preliminary Prospectus
Supplement and updates and supersedes the information in the Preliminary Prospectus Supplement to the extent it is inconsistent with
the information in the Preliminary Prospectus Supplement. Terms used and not defined herein have the meanings assigned in the
Preliminary Prospectus Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 58%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
    Health, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.625%
    Senior Notes Due 2026 (the &ldquo;Notes&rdquo;)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC
    Registered</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
    Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    15, 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement
    Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    17, 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Listing:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
    &ldquo;HROWL&rdquo; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    Proceeds:</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Notes:</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$18,025,000</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">700,000
    (equal to $17,500,000 principal amount)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    Notes:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
    to 100,000 (up to $2,500,000 of additional principal amount)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturity
    Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    30, 2026</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rating:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Notes have received a &ldquo;BB&rdquo; rating from Egan-Jones Ratings Co., an independent, unaffiliated rating agency. Ratings are
    not a recommendation to purchase, hold or sell notes, inasmuch as the ratings do not comment as to market price or suitability for
    a particular investor. The ratings are based upon current information furnished to the rating agency by the Issuer and information
    obtained by the rating agency from other sources. The ratings are only accurate as of the date thereof and may be changed, superseded
    or withdrawn as a result of changes in, or unavailability of, such information, and therefore a prospective purchaser should check
    the current ratings before purchasing the Notes. Each rating should be evaluated independently of any other rating.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
    Coupon:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.625%,
    paid quarterly in arrears</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 34; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    Payment Dates:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 58%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    31, April 30, July 31 and October 31, commencing July 31, 2021, and at maturity </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price
    to the Public:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$25.75</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Day
    Count:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30/360
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Optional
    Redemption:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
    to February 1, 2026, the Issuer may, at its option, redeem the Notes, in whole at any time or in part from time to time, at a redemption
    price equal to 100% of the principal amount of the Notes to be redeemed, plus a Make-Whole Amount, if any, plus accrued and unpaid
    interest to, but excluding, the date of redemption.</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Issuer may redeem the Notes for cash in whole or in part at any time at our option on or after February 1, 2026 and prior to maturity,
    at a price equal to 100% of their principal amount, plus accrued and unpaid interest to, but excluding, the date of redemption.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minimum
    Denomination / Multiples:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$25.00/$25.00
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CUSIP/ISIN:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">415858
    208/US4158582084</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Book-Running
    Managers:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
    Riley Securities, Inc., Ladenburg Thalmann &amp; Co. Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conflict
    of Interest:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
    Riley Securities, Inc. will participate in the offering of the Notes as a joint book-running manager.</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
    Riley Securities, Inc. has a &ldquo;conflict of interest&rdquo; in this offering within the meaning of Rule 5121 of the Financial
    Industry Regulatory Authority (&ldquo;FINRA&rdquo;). Accordingly, this offering will be made in compliance with the applicable provisions
    of FINRA Rule 5121.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>This
communication is intended for the sole use of the person to whom it is provided by the issuer.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuer has filed a shelf registration statement (including a base prospectus dated July 13, 2020) and Preliminary Prospectus Supplement
with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) for the offering to which this communication relates. Before you invest,
you should read the prospectus in that registration statement, the Preliminary Prospectus Supplement and other documents the issuer has
filed with the SEC for more complete information about the issuer and this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may get these documents for free by visiting EDGAR on the SEC Web site at <I>www.sec.gov. </I><B>Alternatively, the issuer, any underwriter
or any dealer participating in the offering will arrange to send you the prospectus and related preliminary prospectus supplement if
you request them from B. Riley Securities, Inc. by calling (703) 312-9580 or by emailing prospectuses@brileysecurities.com.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANY
DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS
OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER E-MAIL SYSTEM.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 7pt Avenir LT 35 Light; width: 100%; border-collapse: collapse">
  <TR>
    <TD ROWSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; width: 48%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_01.jpg" ALT="" STYLE="height: 48px; width: 150px"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 28%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">511
    Union Street, Suite 2700</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 16%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">615.244.6380</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 8%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">main</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">P.O.
    Box 198966</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">615.244.6804</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fax</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nashville,
    TN 37219-8966</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">wallerlaw.com</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
17, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Health, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">102
Woodmont Blvd., Suite 610</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nashville,
Tennessee 37205</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
                                            Health, Inc.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our capacity as special securities counsel to Harrow Health, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), in connection
with the issuance of $20,000,000 aggregate principal amount of the Company&rsquo;s 8.625% Senior Notes due 2026 (the &ldquo;Notes&rdquo;),
we have examined (i) the Registration Statement on Form S-3 (Registration No. 333-239669) filed by the Company under the Securities Act
of 1933, as amended, (ii) the related Prospectus, dated July 13, 2020 (the &ldquo;Prospectus&rdquo;), as supplemented by the Prospectus
Supplement, dated June 14, 2021 (the &ldquo;Prospectus Supplement&rdquo;), and (iii) the base Indenture, dated as of April 20, 2021,
between the Company and U.S. Bank National Association (the &ldquo;Trustee&rdquo;), as supplemented by the First Supplemental Indenture
dated as of April 20, 2021 (collectively, the &ldquo;Indenture&rdquo;). In this regard, we have examined and relied upon such records,
documents and other instruments as in our judgment are necessary or appropriate in order to express the opinions hereinafter set forth
and have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, and the conformity
to original documents of all documents submitted to us as certified or photostatic copies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
assume for purposes of this opinion that the Trustee is duly organized, validly existing and in good standing under the laws of its jurisdiction
of organization; that the Trustee is duly qualified to engage in activities contemplated by the Indenture; that the Indenture has been
duly authorized, executed and delivered by the Trustee and constitutes the legally valid and binding obligation of the Trustee enforceable
against the Trustee in accordance with its terms; that the Trustee is in compliance, with respect to acting as a trustee under the Indenture,
with all applicable laws and regulations; and that the Trustee has the requisite organizational and legal power and authority to perform
its obligations under the Indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the foregoing, we are of the opinion that the Notes have been duly authorized by all necessary corporate action on the part of the
Company and, when authenticated and delivered by the Trustee and issued by the Company in accordance with the terms of the Indenture
and the Underwriting Agreement, dated June 14, 2021 (the &ldquo;Underwriting Agreement&rdquo;), by and between the Company and B. Riley
Securities, Inc., as representative of the several underwriters listed on <U>Schedule A</U> to the Underwriting Agreement, and in the
manner and on the terms described in the Prospectus and the Prospectus Supplement, the Notes will be valid and binding obligations of
the Company enforceable in accordance with their terms, except as enforceability may be limited by bankruptcy, insolvency, reorganization
or other similar laws relating to creditors&rsquo; rights or by general principles of equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing opinion is limited to matters arising under the laws of the State of New York and the General Corporation Law of the State
of Delaware as in effect on the date hereof. We hereby consent to the filing of this opinion as an exhibit to the Company&rsquo;s current
report on Form 8-K and further consent to the reference to us under the caption &ldquo;Legal Matters&rdquo; in the Prospectus and the
Prospectus Supplement. This consent is not to be construed as an admission that we are a party whose consent is required to be filed
with the Prospectus or the Prospectus Supplement under the provisions of the Securities Act of 1933, as amended, or the rules and regulations
of the Securities and Exchange Commission promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Waller Lansden Dortch &amp; Davis, LLP</I></FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex5-1_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  \ +P# 2(  A$! Q$!_\0
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MKOOB#_R+/_;=/ZT0K2J8>?-N@MJ9OPT_X]]2_P!^/^1J3XE?\>%A_P!=F_\
M0:C^&G_'OJ7^_'_(U)\2O^/"P_Z[-_Z#27^X_P!=PZEGX=?\@"?_ *^&_P#0
M5JMK?CY["_GL[6R5GA<H9)6X)'H!_C5GX=?\@"?_ *^&_P#05KB-; /BZ\!
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3.>PK?HHIPA&"Y8JR ****H#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="logo_001.jpg" ALT="" STYLE="height: 82px; width: 207px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT
99.1</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Health Announces Pricing of $17.5 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASHVILLE,
Tenn., June 14, 2021 &ndash; Harrow Health, Inc. (NASDAQ: HROW) (&ldquo;Harrow Health&rdquo; or the &ldquo;Company&rdquo;), an ophthalmic-focused
healthcare company, today announced the pricing of its underwritten registered public offering of $17.5 million aggregate principal amount
of 8.625% senior notes due 2026 (the &ldquo;Notes&rdquo;). The Company has granted the underwriters a 30-day option to purchase an additional
$2.5 million aggregate principal amount of Notes in connection with the offering. The Notes will be treated as a single series with the
Company&rsquo;s outstanding 8.625% senior notes due 2026 and will trade interchangeably with the existing notes. The Notes will be sold
to investors at a price of $25.75 per Note, for aggregate gross proceeds of $18,025,000. The offering is expected to close on June 17,
2021, subject to customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Health and this issuance of Notes both received a rating of &ldquo;BB&rdquo; from Egan-Jones Ratings Company, an independent, unaffiliated
rating agency. The outstanding Notes are listed, and the new Notes to be issued are expected to be listed, on the Nasdaq Global Market
under the symbol &ldquo;HROWL&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects to use the net proceeds of the offering to redeem all outstanding shares of its Series B Cumulative Preferred Stock,
with the remaining net proceeds available for general corporate purposes, including funding future strategic product acquisitions and
related investments, making capital expenditures and funding working capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Riley Securities, Inc. and Ladenburg Thalmann &amp; Co. Inc. are acting as joint book-running managers for this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes will be offered under the Company&rsquo;s shelf registration statement on Form S-3, which was declared effective by the Securities
and Exchange Commission (&ldquo;SEC&rdquo;) on July 13, 2020. The offering of these Notes will be made only by means of a prospectus
supplement and accompanying base prospectus, which will be filed with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copies
of the prospectus supplement and the accompanying base prospectus may be obtained on the SEC&rsquo;s website at <U>www.sec.gov</U>, or
by contacting B. Riley Securities by phone at (703) 312-9580, or by emailing <U>prospectuses@brileyfin.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the Notes
in any state or jurisdiction in which such offer, sale or solicitation would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-MORE-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Harrow Health</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, one of the nation&rsquo;s
leading ophthalmology outsourcing and pharmaceutical compounding businesses, and Visionology, a direct-to-consumer eye care subsidiary
focused on chronic eye disease. Harrow Health also holds non-controlling equity positions in Eton Pharmaceuticals, Surface Ophthalmics
and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries. Harrow Health also owns royalty rights in four clinical
stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please
visit the Investors section of our corporate website, <U>harrowinc.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains &ldquo;forward-looking statements&rdquo; within the meaning of the U.S. Private Securities Litigation Reform Act
of 1995. Any statements in this release that are not historical facts may be considered such &ldquo;forward-looking statements.&rdquo;
Such forward looking statements include, but are not limited to, statements regarding the terms and conditions and timing of the senior
notes offering and the intended use of proceeds. Because these forward-looking statements involve known and unknown risks and uncertainties,
there are important factors that could cause actual results, events or developments to differ materially from those expressed or implied
by these forward-looking statements. Factors that could cause actual results to differ include (without limitation) the possibility that
the notes offering will not be consummated at the expected time, on the expected terms, or at all. Additional risks and uncertainties
are more fully described in Harrow Health&rsquo;s filings with the Securities and Exchange Commission, including its Annual Report on
Form 10-K for the year ended December 31, 2020 and Quarterly Report on Form 10-Q for the three months ended March 31, 2021. Such documents
may be read free of charge on the SEC&rsquo;s web site at <U>www.sec.gov</U>. Undue reliance should not be placed on forward- looking
statements, which speak only as of the date they are made. Except as required by law, Harrow Health undertakes no obligation to update
any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence
of unanticipated events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contact:</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jamie
Webb, Director of Communications and Investor Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>jwebb@harrowinc.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">615-733-4737</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-END-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>logo_001.jpg
<TEXT>
begin 644 logo_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !2 ,\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V2BBJ6J:O
M8:):&YU.[BMH,[0TAQD^@]30(NT5YKK/QHTVVW)I%G->/VDE_=I_B?R%<%K/
MQ)\1ZT61K[[+$?\ EE:_)Q]>I_.M%3DS-U8H]TU7Q+H^A@?VGJ-O;D_PLV6_
M[Y'-6;#5++58!-I]W#<QG^*)PV/KZ5\LLQ=R[$LYZL3DG\:EM;JXL9Q-:3RP
M2CH\3E3^8J_8Z;D>WUV/JNBO!]&^+GB#3=J7C1:C$/\ GL-K_P#?0_J#7?:-
M\7/#^I;4O&ETZ8]IAE/^^A_7%9NG)&D:D6=U14<$\5U DT$B212 ,CH<AAZ@
MU)4%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %><_&O_D5[+_K
M\'_H#5Z-7G7QK_Y%:R_Z_!_Z U7#XD34^%GFFE:9:O9Q3R1[W8'[QXZ^E>L^
M$_#FDZUX/ACU'3[><"20 L@#+\W8CD5YAI'_ ""H/H?YFO8?A_\ \BI%_P!=
M7_\ 0JZ*VD#DH:S=SQ[XB^';+PSXE6TTT2"!X%EVNV[:22, ^G%9>C:?!=Q2
M23J6*M@#/'2NH^,W_(YP_P#7FG_H35@^'?\ CTF_ZZ?TIT]4KBK:-V.ET7PG
M-KXDAL[>W\F+&\R8 7/3W/2L_P ?>!H?"-E8S1W!EEN9&5U PB@#/'>O0/AC
M_JM2_P!Z/^1K*^.'_(-TC_KO)_Z"*F4WS\I<(+V?-U.N\&3QVOP^TJ:9@D45
MDKNQZ* ,DUH:1XBTK7C*-*OH;KR@"_ED_+GI_(U@Z3_R2"/_ +!3?^@&O-/A
MMXRT_P (&_;4([A_M(C">2@.-N<YR1ZBL>6]V;\]K(]EN_%.BV&IKIUWJ,$5
MZQ4"%B=Q+?=_.M4D $G@#K7S_K.NVWB7XEV>I62RK#)/;J!*N&R" :]4^)FO
M?V%X0N/+?;<WA^SQ<\C/WC^ S^E)PM9#4[W?8U-,\7Z%K-]]CT[4X+BXP6\M
M<Y('7J*T;Z_MM,LI+N]F6"WB&7D;HHZ5\YV*7_A&[T/760K'-F:+'\2!MK*?
MJ/YU[1X_N(KSX::E<0,&BEMT=&'<%E(IRA9JP1G=.Y9_X6%X6_Z#=I^9_P *
MV-/U6QU:W\_3KN&ZBS@M$X;!]_2O$/!/A[PMJ^DW,WB'4OLEPDQ5%^T+'E=H
M.<$<\YJ;X7.UK\2'MM.F>6R99E9\8$D:_=8CZX_.FX+6W0E5'I?J>I-X_P#"
MZ.R-K5J&4E2,G@C\*O:7XFT?6I#'INI6US(!DHC_ #8^G6O"/#&F:1JOBRZM
M]>NOLUG^];?YHC^;=P,G\:77;33]"\96B^%+][H(T;)(KABLA;[H8=>WYXI^
MS6P>T>Y]"75W!96[W%U-'#"@RTDC!5'XFL&+XB>%IK@0IK-OO)P"VY5/_ B,
M5YO\2+^]\2>/(/#T,FR&)XX43^$R/@ECZXSC\/>M[5?@WID6A2FPN;K[?%&6
M#R,"DA S@KCC/MTJ>5)*X^9MOE.^U/7M,T:VBN=1O8K>"4[4D8_*QQG@CVJ:
MQU*TU.Q2]LKA)[9P2LJ'Y3CK_*O#_"\MQXB\$:WH$A:7['"+ZSR<F,J?F4>Q
M[?4U8\+>+?[,^&.NV?F8G1@MN,\XEX./IAC0Z8>T/7=)\4:-KL\D.EZA#=2Q
MKN=4)R!G&:;J'BO1-*OA97^I007+ $1,3NYZ?G7AWP_U&3P_XSTR:93'!=#R
MB6X#(_ ;Z;@/RK:T9/\ A,_C'+=,-]O!.TW/39'\J?F<4W3LQ*I='MU%%%9&
MH5YU\:_^16LO^OP?^@-7HM>=?&O_ )%:R_Z_!_Z U7#XD34^%GGVD?\ (*@^
MA_F:]*\+^*-,T3PO%%=S$S^8Y\J-=S8S^E>:Z1_R"X/H?YFNW\,^"EURR6]N
M+LQPEBNR-?F.#CJ>E=511Y?>.&DY<_N[G/>,9[;Q5KRZ@R20QI$(A&6&3@DY
M)_&GZ/X6O[M NFZ?((B<[V&U?S->FQ:'X=\-0_:)UMH@O_+:Z<$_F?Z5G7'Q
M,T8*XTWS+XH=N4&U,_4_T%9JIT@C65+[521=\'>'+CP]!<_:I8G><J=L><+C
M/?OUKD_CC_R#=(_Z[R?^@BNL\(^([GQ$;U[B**)864(J9/7/4GKTKD_CA_R#
M=(_Z[R?^@BLU?VGO&WN^R]W8Z#2?^201?]@IO_0#7!_"'0=+UUM4&J6,5T(E
MBV>:,[<[LX_(5Z+X7F:W^&=A,@4M'IX8!AD9"YYKE8?'6LI TT5M:+&" [I
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MAH>F#1=#L].$IE%K$L?F$8W8[XJ_1161J%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !0*** "BBB@ HHHH **** "BBB@ HHHH *
6*** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>7
<FILENAME>ex99-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="logo_002.jpg" ALT="" STYLE="height: 82px; width: 207px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Harrow
Health Announces Closing of $20 Million Aggregate Principal Amount Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
8.625% Senior Notes Due 2026</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASHVILLE,
Tenn., June 17, 2021 &ndash; Harrow Health, Inc. (NASDAQ: HROW) (&ldquo;Harrow Health&rdquo; or the &ldquo;Company&rdquo;), an ophthalmic-focused
healthcare company, today announced the closing of its underwritten registered public offering of $20 million aggregate principal amount
of 8.625% senior notes due 2026 (the &ldquo;Notes&rdquo;), which includes the full exercise of the over-allotment option of $2.5 million
aggregate principal amount granted to the underwriters. The Notes will be treated as a single series with the Company&rsquo;s outstanding
8.625% senior notes due 2026 and will trade interchangeably with the existing notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Health and this issuance of Notes both received a rating of &ldquo;BB&rdquo; from Egan-Jones Ratings Company, an independent, unaffiliated
rating agency. The Notes will trade on Nasdaq under the symbol &ldquo;HROWL&rdquo; following the closing date of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering resulted in net proceeds of approximately $19.6 million after deducting underwriting discounts and commission, but before expenses.
The Company expects to use the net proceeds of the offering to redeem all outstanding shares of its Series B Cumulative Preferred Stock,
with the remaining net proceeds available for general corporate purposes, including funding future strategic product acquisitions and
related investments, making capital expenditures and funding working capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Riley Securities, Inc. and Ladenburg Thalmann &amp; Co. Inc. acted as joint book-running managers for this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waller
Lansden Dortch &amp; Davis, LLP acted as legal counsel to the Company. Duane Morris LLP acted as legal counsel to the underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes were offered under the Company&rsquo;s shelf registration statement on Form S-3, which was declared effective by the Securities
and Exchange Commission (&ldquo;SEC&rdquo;) on July 13, 2020. The offering of these Notes was made only by means of a prospectus supplement
and accompanying base prospectus, each of which was previously filed with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copies
of the prospectus supplement and the accompanying base prospectus may be obtained on the SEC&rsquo;s website at <U>www.sec.gov</U>, or
by contacting B. Riley Securities by phone at (703) 312-9580, or by emailing <U>prospectuses@brileyfin.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the Notes
in any state or jurisdiction in which such offer, sale or solicitation would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-MORE-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Harrow Health</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, one of the nation&rsquo;s
leading ophthalmology outsourcing and pharmaceutical compounding businesses, and Visionology, a direct-to-consumer eye care subsidiary
focused on chronic eye disease. Harrow Health also holds non-controlling equity positions in Eton Pharmaceuticals, Surface Ophthalmics
and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries. Harrow Health also owns royalty rights in four clinical
stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please
visit the Investors section of our corporate website, <U>harrowinc.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains &ldquo;forward-looking statements&rdquo; within the meaning of the U.S. Private Securities Litigation Reform Act
of 1995. Any statements in this release that are not historical facts may be considered such &ldquo;forward-looking statements.&rdquo;
Such forward looking statements include, but are not limited to, statements regarding the intended use of proceeds. Because these forward-looking
statements involve known and unknown risks and uncertainties, there are important factors that could cause actual results, events or
developments to differ materially from those expressed or implied by these forward-looking statements. Additional risks and uncertainties
are more fully described in Harrow Health&rsquo;s filings with the Securities and Exchange Commission, including its Annual Report on
Form 10-K for the year ended December 31, 2020 and Quarterly Report on Form 10-Q for the three months ended March 31, 2021. Such documents
may be read free of charge on the SEC&rsquo;s web site at <U>www.sec.gov</U>. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. Except as required by law, Harrow Health undertakes no obligation to update
any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence
of unanticipated events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jamie
Webb, Director of Communications and Investor Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>jwebb@harrowinc.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">615-733-4737</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-END-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>logo_002.jpg
<TEXT>
begin 644 logo_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !2 ,\# 2(  A$! Q$!_\0
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MB@ HHHH **** "BBB@ KRCX^_P#(G:=_U_K_ .@/7J]>4?'W_D3M._Z_U_\
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IHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>hrow-20210617.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.8a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWamFGbP9z5Z82ekhvWB9bbnKDyUjM0X/eiQdwYXmsZAF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:HROW="http://harrowinc.com/20210617" elementFormDefault="qualified" targetNamespace="http://harrowinc.com/20210617">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://harrowinc.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="hrow-20210617_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="hrow-20210617_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="hrow-20210617_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="HROW_CommonStock0.001ParValuePerShareMember" name="CommonStock0.001ParValuePerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_Sec8.625SeniorNotesDue2026Member" name="Sec8.625SeniorNotesDue2026Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>hrow-20210617_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.8a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://harrowinc.com/role/Cover" xlink:href="hrow-20210617.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliateCollateralizedSecurityLineItems" xlink:label="loc_srtAffiliateCollateralizedSecurityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20210617.xsd#HROW_CommonStock0.001ParValuePerShareMember" xlink:label="loc_HROWCommonStock0.001ParValuePerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_HROWCommonStock0.001ParValuePerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="hrow-20210617.xsd#HROW_Sec8.625SeniorNotesDue2026Member" xlink:label="loc_HROWSec8.625SeniorNotesDue2026Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_HROWSec8.625SeniorNotesDue2026Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>hrow-20210617_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.8a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20210617.xsd#HROW_CommonStock0.001ParValuePerShareMember" xlink:label="HROW_CommonStock0.001ParValuePerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStock0.001ParValuePerShareMember" xlink:to="HROW_CommonStock0.001ParValuePerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CommonStock0.001ParValuePerShareMember_lbl" xml:lang="en-US">Common Stock, $0.001 par value per share [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20210617.xsd#HROW_Sec8.625SeniorNotesDue2026Member" xlink:label="HROW_Sec8.625SeniorNotesDue2026Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_Sec8.625SeniorNotesDue2026Member" xlink:to="HROW_Sec8.625SeniorNotesDue2026Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_Sec8.625SeniorNotesDue2026Member_lbl" xml:lang="en-US">8.625% Senior Notes due 2026 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliateCollateralizedSecurityLineItems" xlink:label="srt_AffiliateCollateralizedSecurityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AffiliateCollateralizedSecurityLineItems" xlink:to="srt_AffiliateCollateralizedSecurityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AffiliateCollateralizedSecurityLineItems_lbl" xml:lang="en-US">Affiliate, Collateralized Security [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_Sec8.625SeniorNotesDue2026Member" xlink:to="HROW_Sec8.625SeniorNotesDue2026Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_Sec8.625SeniorNotesDue2026Member_doc" xml:lang="en-US">Sec8.625SeniorNotesDue2026 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStock0.001ParValuePerShareMember" xlink:to="HROW_CommonStock0.001ParValuePerShareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CommonStock0.001ParValuePerShareMember_doc" xml:lang="en-US">Common Stock, $0.001 par value per share [Member]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>hrow-20210617_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.8a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://harrowinc.com/role/Cover" xlink:href="hrow-20210617.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliateCollateralizedSecurityLineItems" xlink:label="loc_srtAffiliateCollateralizedSecurityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtAffiliateCollateralizedSecurityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20210617.xsd#HROW_CommonStock0.001ParValuePerShareMember" xlink:label="loc_HROWCommonStock0.001ParValuePerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_HROWCommonStock0.001ParValuePerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20210617.xsd#HROW_Sec8.625SeniorNotesDue2026Member" xlink:label="loc_HROWSec8.625SeniorNotesDue2026Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_HROWSec8.625SeniorNotesDue2026Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:HROW="http://harrowinc.com/20210617"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hrow-20210617.xsd" xlink:type="simple"/>
    <context id="From2021-06-17to2021-06-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
        </entity>
        <period>
            <startDate>2021-06-17</startDate>
            <endDate>2021-06-17</endDate>
        </period>
    </context>
    <context id="From2021-06-172021-06-17_custom_CommonStock0.001ParValuePerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">HROW:CommonStock0.001ParValuePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-17</startDate>
            <endDate>2021-06-17</endDate>
        </period>
    </context>
    <context id="From2021-06-172021-06-17_custom_Sec8.625SeniorNotesDue2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">HROW:Sec8.625SeniorNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-17</startDate>
            <endDate>2021-06-17</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-06-17to2021-06-17">0001360214</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-06-17to2021-06-17">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-06-17to2021-06-17">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-06-17to2021-06-17">2021-06-17</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-06-17to2021-06-17">HARROW HEALTH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-06-17to2021-06-17">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-06-17to2021-06-17">001-35814</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-06-17to2021-06-17">45-0567010</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-06-17to2021-06-17">102     Woodmont Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-06-17to2021-06-17">Suite 610</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-06-17to2021-06-17">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-06-17to2021-06-17">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-06-17to2021-06-17">37205</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-06-17to2021-06-17">(615)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-06-17to2021-06-17">733-4730</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2021-06-172021-06-17_custom_CommonStock0.001ParValuePerShareMember">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-06-172021-06-17_custom_CommonStock0.001ParValuePerShareMember">HROW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-06-172021-06-17_custom_CommonStock0.001ParValuePerShareMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="From2021-06-172021-06-17_custom_Sec8.625SeniorNotesDue2026Member">8.625% Senior Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-06-172021-06-17_custom_Sec8.625SeniorNotesDue2026Member">HROWL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-06-172021-06-17_custom_Sec8.625SeniorNotesDue2026Member">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="From2021-06-17to2021-06-17">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-06-17to2021-06-17">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-06-17to2021-06-17">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-06-17to2021-06-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-06-17to2021-06-17">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140404130648760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 17, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_AffiliateCollateralizedSecurityLineItems', window );"><strong>Affiliate, Collateralized Security [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 17,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HARROW
HEALTH, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001360214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-0567010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">102
    Woodmont Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(615)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">733-4730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=HROW_CommonStock0.001ParValuePerShareMember', window );">Common Stock, $0.001 par value per share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_AffiliateCollateralizedSecurityLineItems', window );"><strong>Affiliate, Collateralized Security [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HROW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=HROW_Sec8.625SeniorNotesDue2026Member', window );">8.625% Senior Notes due 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_AffiliateCollateralizedSecurityLineItems', window );"><strong>Affiliate, Collateralized Security [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">8.625% Senior Notes due 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HROWL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_AffiliateCollateralizedSecurityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_AffiliateCollateralizedSecurityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=HROW_CommonStock0.001ParValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=HROW_CommonStock0.001ParValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=HROW_Sec8.625SeniorNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=HROW_Sec8.625SeniorNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M%'?JF>+G'J2'PQVV&P]A0N.*/ 9!=?UJ]&K)2O.GN%/_BVR2IAF0U0+BLK6
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M#%8G<P#\'D@HR7['O+PJWCT._P902P,$%     @ [('14I^@&_"Q @  X@P
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MB^$_7G\!4$L! A0#%     @ [('14@=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #L@=%2W8,1@NX
M   K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"
M% ,4    " #L@=%2F5R<(Q &  "<)P  $P              @ ', 0  >&PO
M=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .R!T5+SF*G8TP0  (<4   8
M              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"
M% ,4    " #L@=%2GZ ;\+$"  #B#   #0              @ $6#0  >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( .R!T5*7BKL<P    !,"   +
M      "  ?(/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( .R!T5*JQ"(6,P$
M "("   /              "  =L0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " #L@=%2)!Z;HJT   #X 0  &@              @ $[$@  >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #L@=%299!YDAD!  #/
M P  $P              @ $@$P  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    "0 ) #X"  !J%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>ex1-1.htm</File>
    <File>ex5-1.htm</File>
    <File>ex99-1.htm</File>
    <File>ex99-2.htm</File>
    <File>hrow-20210617.xsd</File>
    <File>hrow-20210617_def.xml</File>
    <File>hrow-20210617_lab.xml</File>
    <File>hrow-20210617_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "hrow-20210617_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "hrow-20210617_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hrow-20210617_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "hrow-20210617.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd"
     ]
    }
   },
   "elementCount": 65,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 2,
   "memberStandard": 0,
   "nsprefix": "HROW",
   "nsuri": "http://harrowinc.com/20210617",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2021-06-17to2021-06-17",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://harrowinc.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2021-06-17to2021-06-17",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "HROW_CommonStock0.001ParValuePerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, $0.001 par value per share [Member]",
        "label": "Common Stock, $0.001 par value per share [Member]"
       }
      }
     },
     "localname": "CommonStock0.001ParValuePerShareMember",
     "nsuri": "http://harrowinc.com/20210617",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_Sec8.625SeniorNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sec8.625SeniorNotesDue2026 [Member]",
        "label": "8.625% Senior Notes due 2026 [Member]"
       }
      }
     },
     "localname": "Sec8.625SeniorNotesDue2026Member",
     "nsuri": "http://harrowinc.com/20210617",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_AffiliateCollateralizedSecurityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliate, Collateralized Security [Line Items]"
       }
      }
     },
     "localname": "AffiliateCollateralizedSecurityLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001493152-21-014657-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-21-014657-xbrl.zip
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MT]6OB[F_'5DRI6\\UV^TDRG>Z^S*OGN.R((W^'\X*_@OK$_'4HW+)/IP:YS
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M)+R7@Q,O%FCV@%7R6X*.78X%XYP&&[FQBZ=/7OQVYF6&C-G)KQ;R5B;>29"
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MC=$OGW)8[&$.^'*8P=&C3S+T;P9S/@0;]DF@),E.JK4VY DV>4]JH\;50!R
M@Z.%P66GL8"-6AC'&Z%?U0+%1BKH=0I&QXE;M 7"9R$T&&0S4^K$TORRL\$M
M[Z1<H!D0@!E'7&)B0A3B\G/0-IE@0JR!9I%42NM-G!7DXB);IL2-#4 BH:.
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MZ0HL9AL0VX#1O8G79<6"!RUD>BR06QZ42H_AX*6D#YX59;F X_(:JU4I-V&
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M\.@>]-&7G]AF6:_F^%=ENTX/V:[M9KM.#]FN/<IV_44DSK=K!U]>[BHU9BK
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MH.P3>\$%=E .U*+A @E3\HJ>:<V>3DQP>1TZD#7;(;J1-.L0;B!.9O-:F^O
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M\R$:L(EN4SL;BD])KVO.?O3H*)3&;$B0B4U1,A9PCIU*MZ$S%]=KD.([;UH
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M*4X\ *0 VSB%0+O(\ 3_AV!:!#WIFMPGG0RGTE"D84YBO8F4!&+R0+LZ(AD
M$5B!A?-R">NR%04YWR/8(\(WHC@C)/$D,I%&>TL/XF.TX_T<ENX:[?]!@^LC
MNM 5&]4@BQ-,'2VT&P7HJ+1B\88;6R9IXV.\8 8$5/EC'D(@NNX"IONX)"X!
MW#(<V])"*XQQU&0H@]"GBSE*8])911*E]!EXK7V9#C%<3.5:Y-F_7OW7!$IM
MO5&KA6,^MMW'"3BRF0L\FL8.XE-46D!(0?+B&CI0LR'P$;A *JBYT W617&)
MR6)20/$!*#C@Y&(SX^A#J$403$+#TCH+: H@S0;)KAA*%Y!HB(P[A$T'<"9'
M4$=Z@@\#RM*8$R0M1X$\)1"S@]Z.?@HF4&6JUP?-L@5$0]*.JML"&*$Y0Q&D
MN%'BT,O,I+ORA.7S)>49! ? O0!'/-CH$NJ@=IP$UB68X0!FQ12*L9N]7Q.I
MZ=9#,>%$2;#+QHS%T0SZZ7V:"6 <3(V%(KPJE\CC/(9ZG;V_8><7<^40=,4O
ME^PLIDPADV(<H?3L[*;9FK;"%?QQ]-,.2>I1MM*BU(I4E?EHSHBTL,5-3>94
MQEQEC+=<*K @6(!9FH]4_EWM3FS[*B-=TY_TL>W/S,,"'<I&\0>JX!D16/1B
M%W3].QGC^GTY1QLZFG<=_3NLLW/P:LS_G#\O3B9$KHC($(<C4I:9KP5B@BY-
M,MU":19@ ! %"%GGPT'?FPAD2;!NI_'A@%KW[WQ,9X;-"BHI3%L_39J+G"^T
MI^109"L+%'M!9]:RYVJAA&8293(4?PO(E"2PH4*<"I!\37:E<E;2L/ $.@RA
M6^R2 :'7E,])<R#!GES1#$&Z51(;;TX'.AT%%R*DUTH481&#4:7L5&-OP)6#
M7'N (<L16P\%*DVD='I\<X_U$.,C/>"2-EOIT2]PDYXPV,Q_@^0OYLJ >F"!
MC LHE'I1.<CWE!O;<AS\:3V]L@=B.F/3&]+^*5)?%GWR)JV(5X7[#3T^6]IH
M"=GBSH0[#(G1B#A#VI>$3/90$XWJ[*-[.9Q;$D2'I;3G<6JWCJQP2V(;$.@>
M%<O6KMZ$ " IB"J7 $.1RN\5[-;^8WT9)<HVQHI*)48PA?K3'5'R\'@\MLZF
MV-FS7..=BV8*F=?#2[FT%E_J;$".93;@91A94X;"$4*5N/,N_.7^%$-C,=O2
ML<?M7)IC!H&&%P59HJ1<SH?"W0 IW.TIF!.IZP&PX#].JQ=2IR"WYJX)6WO3
M)!6N$H*.%:IGRV1%$"TYOO0F/!S;G&8^0_LT"<9VH%'>A#5L<Q#T$V\J=PX7
M('3U@<<?>$CP)M^-?.<#@S__F9'4X.WFH[M]>N&7,_%/H>;.*( !J.L\2I2N
MKC'Y%WK$YQ=-T;V8]3L-]VE6Y^2@H1O.E(_VT2F0D5"#8+$C3'UOPA[S:;S/
MCCAF5Y4!-3N-DW5/_5Y]:.G6'/#.62IL_%>MQEY+$?A[[(R/Q3X$?$V(OF#C
M/GMO&8O>(T5]]X4/PJ,-J]4ROX]._LP,7)E[.S3WTM&073L,N/>%M>K;\ ^'
M#NG3U_PW>=C@VE&S,I*N)CIOI[7/[:X9T'EEKGN2K* N#^_J%]6=!N*3A:H0
MZP8%VT5Q,X62C?L&_4V*^R,5^EN6_P%02P,$%   " @ [('14O )MGT$#
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M[VW00<Y#M<QK33RCOWN-?PA+?R_['U!+ P04  @(" #T@=%2
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MX<DUKQGCZ^!_];\K,I:T%682/A4V5?E5Z\?1-1MO' R7FCJ>.YH!^-7E22C
M C'M VJS<C %KZ>@;*(9+.6,1E[).%@1 +R/+DJ?BN?@MQO)L6R0N%6]U].U
MIJU+=^DD8.F<FI=4==@Y,SF3_V2]%C/?;4T"-+,.DGZHP"V2 9BAH2J28@M8
MB0PB1!.FKFLS[#9MP"BVKZK4LL[:?+Z5H6+%RJB%=I^&A;W4U '#P*:F0_M'
MDE:323O)8K;09)JBFZ>ZS:P#AT&]XI]!5(_-?TU.NXZF"%H"TV&"''J,6H[)
MRJZ-L0MUO,Z\HN@0V-N,_H7!,G,(%PF\TL)C!(;1Q#A@Q  =3N(6VW+536W=
MG"3#9^!@',9IO88&/6":WE.TQX9]'"_CXT[KV"N/8&$"H:XM$;(<A"'CV7=[
M*6@//_&_>\9S;<FOI$?-CJ+M$JR:_DJ0&!-453KP20)&0GGTG__-%--?]U)&
M^14'\;L/V=L-1V6)<]KA;D'8Y!THLMW%H=-_QR(%+=T$M"1LW=@E^RJ5[D@>
MAK1T59&_$K>PI=L@A[WR3+(0U, 9)2SE 0S\C&$',T<4N_^&P$M%X/OP"V 9
M5!OK>>=Q7V2O5?YU6K^H'6QN-"\J%[7F7JH%N,+.RBL+<;-6_=6H7]1KS<V-
MRND!J5U7CRJGWVND>O;S9[W9K)^=ON\TLD^:QA6UNHK6L74MOKEQD*PF239=
MR)?>%_0G^*\>/:\VD1R>-7X"6+P]*C+T]$OI(@]@)!('NN2@]8&QHQO)C[4$
M49>'6L[^Q7X?*,=GM]#?2]WN\'BQ\D[B>-S']=&Y7OR7@@B+#_*A43N]V-QH
MU,[/&A<KCU4 ^=PQ+8=J]N:&K<-G"4/9)),C9PV2*6S)7XC>)A==AD6.J=@*
M=%<;2EVJ@?ZJ2#869TJY_$>8JD=#JP\I>@*;&X#:!C-TTR9;^ %1S2B8><RR
M">O#(,3DQ4S^LDO&)4YF3.*<<S^B)KR,Z:)G__*ASPSENG2K+"QZPK$W&5TZ
M:->5Z6@$D#-MFFB* !8K_W T1C+;<8*]SI!69$O4RHM:7S["DJX"\3U-@XU3
M4L&E)!'";;".8N'.EXTA[>F$=)'9[N3,VM5#>ADZ;-JXL?)1I=$XN]K<.*I5
M3BZ.XJ1^6DU^5.6V51M2"20PSAFYW/3G2JA%+(-)&'.1B0++8EL$I"\PO?EE
MI><T76';M*4RZ%I5X;O$M\S3,?ZW0679^_O9TPAY=K[#)NFJ2@T+G#+O-Q%)
MV+/-YP_09Z:M2%3UD .NHA>7V+/E!0#N*C9+( X8[L ,3&I,P[X_LUSV[Y<(
MGW&6WHFP=%V3=!,4"=_&YH&XJMAXK>KR# Z7ON]L7ZBW.R?5XC)4!>ZV8]C,
M9H:I]Y$-HKKB"7#&R@=,I0/0,D^1 K;\DM6;LU O6*<QCGDU$)=,2Z4(+1TJ
M*@/$MY@YG7"*E]=&OGI4L-76TE1#,";&K#.)7&%G<C]Q306O2@7Y"!5<T&'=
MW2J0.+?.(XEZ^_IN?]@_RK/2TDAB!@"Q<KZ02!>*V^E,^HD$ O^8JZ(W #TK
MI>.WN! 6T]%-HMM=9I);<!,M6>&.9$3]\TFO%/QZ6T"EA!5+V*Q:/O^M@EQ8
M.3+"'6/%LE:?8%#3"+B$/%G3RIO32KW1%).I]0Q5'^'.[TJ33%0-N<2C)R<H
M)] S*>XDE1=SZ*9I?#$YL;T%7?@?O"VM-&Y:K=V\5W#SYMA?Q>)2[:]JQ/ZJ
MR++)+,O]<:)H+#/=]FI>-K?[MY7.O:4NS?::,GBLG$EG!1ZO=%W&H"#95_OR
MK(A-?"*<^=C\LM/G5U"RUM'H[O8HTW[%^65CY:8##CTI/MFL7/L=RX1QA6ST
M9<>-9\7U([18A5_/S M]H$UG@TKWKI:KWUX7F;1L-@B&CI5/J=7M*ZHZ*P03
M=[$Z-J7<M"EQU^+,/#?U/ICG,\)0JOW/2;&C#SN9-PQ#30<P5KY@F@;?V<3L
MR5O(@%5E_%=7<N<ZK)CZKV+,CE;F'^SL<?I*'YPNF_HC@\?*N>ULNO \#?!9
M1=>6BR$W.M FA@ELHAA4)6S(),=6^KC7 88QL[ZL'O6M*E=L :T)2)#BIB%N
M.7[$'YW)$>PU_N=_=[*9[:] Q393F='5-48T[OK',6JD.NC,$&HR"I)$!B=D
MCM1"35F!FK/EU/V%TSN\K!P/;KM+$%3A\8!PBIG"EUG[Z>,@9UV03W00+N<X
MZWD!W+OLKW;C[-XI2MDE@#T^9JR\G<LE\MNY)YG6AIO4NFHD-97J_P!?V9V#
M'VO@B;.!OX*9N!YJILG8IR7?OMP93[_(&3_5;0%YQ<##![B@C]IZST/,:YH)
M<Q?@?93<(=CDS'2#93PIPB3B&W'-"A"_;5+E:6@R::(!3DZH9;L)4],-BND(
M78*:G!M:^W#*\]:Q;*4]6AC&(%-P<T-DLC 3%LEP$PU).,\PN]7B&89VEV<3
M[BYA9@M'0%^>+[]X\/7/")R.2?/62Z2Y%T[:^7NI#':!Q_Y]GX51J4LD/)'V
MT6-WKX#Z;'K)J#<I4K@ O3GJM71UZQ5=PX^+^&73/&I8E^0U<,[=Y&[X?=!5
M@/X#&;ZJ>1'+C3O-<-]<M3;*9%M<2$SUA6[<\ZQ0?=:!UAOW2"\XA$\Z*'WS
M<-O?-V^/?]^VV,XS_*N%CZ>'?+'Q.<?*H@_".XF3OW@_Q* FZ6-/Q,!CQ=UY
M27BK%E!9U4#/.!D>NF3H2DDA']^.!B];#W(WTZ_0Y^RC+8,$(_,5A\'7M+4,
MVBI?=-GT_9AQB>>=]YF9\/\J%%?M.;?6P;'UX[CP)B0WO@^$BG!R"V@:3D"#
M5IH'E7]F1=>^JWJ+JN0G->^8/858_QA56GDU5?K8]1 W#]^_:[^'UZ?[K>OG
M;($N<!''7/7)F_Y-1&/"6Q,9]":V7XNU)9-;YG54YN.TUOX^K!YJ)>>W=/=F
MM#9%3YZL*>IU%67F517EXW16H+;J7)?:Y[\RKTQGJZ </T%>Y&H%:JM=)MUM
M;F#LE1J&J1NF@L>,6_J0M)BJ#S#$CH48>2<[B6/25E3<[E0LHN"EES*3,9AK
M*3U'M:G&=,=21\2BMF*U1[REVT!O <"41WS=6&_HA*,#_9B;&U0;>85M757Q
M&LL.P30<!?/"K65$AB.H7&>\OL[!1@%P.IDM*-K28S!7(%V \-"D=S0WI=J:
MOBF=N7TP;R_U3I8MGOGYE(LDIX*$5%+:SN>_OJX&]I&=>0&NEWM88#$87"2*
M@:4(*B/[1GAU$LEG"T)H<&$1NI<"KZ/8RFR3ZF&#9'/I)%3\LJI^UH=>KM6$
MX5,L[ZQSE4V=WVH(BN0GZ&A0U-,=F8=\7?EA2;\N:B?/B9H\7^Q-PO,F,N]#
MDVR ,S%VS\7<I(C+Y&DBDPU)N<B5.[Z,RX/DYS778N[/@>%3+.^L"RG.38:6
M%%Z S:\M0R?#/&NW9Z4>7G?O+T=G]?V3^]RKBKO9<*W%WF/- '<)*82\IUEY
MF;R<X-E!3Q*"HNY:#/XY,'R*Y1T7@[7I8K!N60XS'Q6&YJAV>E*__&T?T+<4
MAA/0K47B*XG$'$ODMZ2GB42W[@R1^%IG0UX:DOP(8=.Z)N,:L<V-UHA(&$/%
MT>[(H,OX!2AC\4W%(C *+#,"U"$=4Q_875QK T.>U"(R:RN:N-U-Q#?2!2\2
M.A;<$'=MYC ;6A!$MI7(\GLB9U;.[Y+:C*'G7PKFM?K.&U5%FQF'R'^>G/Y[
M5CS-[R]^;.4I<F<.8$\6.2^EJ&>D>JNL_;GW#^IM$;:?0=MX0DIP"HDRBC*Q
M!] %-F JDVQ@ TWG$L^Q&*\%\+H[#?C:FL(W$<2;"$@S?"QUQ%WJ@0)C(SP:
M  Q%)NLK%C0$[J*:A'XVE?B+8@@JOG4G4U.VQ!Z#/"M!/;=%_03UL+!-$I_@
MWIZR_H!#!./0+?E^_T@"[M1#1J$7 !#J][G?_YUI(HIWG-)7J'_OH-D"W7XE
M9P8W57:Q7X]E^*2Y036Y G/.<8W-K\CW7H-=M? NVO@N6W2,R>VQL6VT\'**
M+=[ @YCB%TP5ZH&M.">Q7!#B^*$CS_;RGN"80)7)Z%VBQ4"Z 80&1WJ8&OXP
MS(0YZZ5,]=9) &]X[?.+Y6VK7+=9;W,CDTQG2 UO5<5-?IU0X@7XR0$:J@H_
MN%_IF(Q[+LDWFYK[$6P*AIVFDR_98'Y#%;A4N,^TS8W(W>=Q<L0?_21'C*IV
M-T[JFI0D6VBNX-GU+$PR/!('16:2>]?AKG E\45;GMJ/9IN+%-XZ\_4+X7S"
MW1.D!DVT&)A\'X-0CPX6&_)7J*_-#9^HQD'@EMU^DC04E8U"?HZ8;1R=*),9
M)K.@+74OEN 6F\5 ; 'E^C ST^(.A8S%)@.7ZV5P0W]CP,8W-\*&I#A"@V-4
M/8\/9RD29T!:XT\L#?=(_LILQPOI=#R=3D-UJ-]!(SJX0(/VT(S%2<[+)]W<
M6&ANAXK9$SV-+X.A.A9Q#"+H -4.-@9X_LHN!=PPWF  G1L7^ <4@.4-#D%H
M3-%XH1E6QGJ)SA/(2</EZ0AOGM,>SX+R\1+'OS<WGCOL-)PF^=L:8B[4A F2
MMF/R<14+<2&Q$-HL@38M@K8X5A!4]E>A@&LP:QW 61,+,0!^T1V;NT BRPJ[
M=0E1QP@>?ET(M;4AN'38^BF3M<'208\/P*'$@E8J<JR) 0S$NLA,B_88"GT)
M@>I /QT=N%S#.I,-XD3VQ@ \56"J*J!-R,[%IKB/A%CW!I_D?KRQWS$,E4LR
M&+DU\LC'LDG3+P'B\SM9/I#S1IL$&4!$FF\Q>\"8%I56\/U7LIDD^U2[(Z?4
MY9N*9>G@4N-?7/S:)B@[!A/A[ *2V !OP",IEU71Z$0?H<_4$6>A9\]JUA0P
M#"&3+NV+D(&%-P: (.U9'+1)(MK2W4 =U5Q2 GD L_)I'U8 .(_+ 2S& #=?
MH@@)1\>K_FK6SS<WQ.4PHJE)9<8S)4T1-P#C=A3(DRA,$=YPQQV#&EFF[6@=
M!2U_C'WP=6DSF:LXO,,8ITV'*"X-W8(^5]OD_*@V&$\'%TLR !M"4,U8_"C$
M0MX50L3J,C5XVX/K-LO+ L?3MCS-MIG(D:U&N,ZIGB2Y7"Z1S96*Q=*7N"OL
M08AO;@"?J!3'9@ #9RU/W(2"P4A.?N@JN&IY82,Q>E6S;QU CS\<(/!,C@NN
M]&+]AZ>^N>%GR4]HDC,<+6('AZ46YU\YJL\0#;K7JAAN%;&]V!#8E<<-H4@Q
M72N$OX[EFR'\MHHQ(R($TG:X<W]\UR05A".IP*!RF.DY*5FZRBU#1>LSR]8!
M'&J#;A3B"&\K_RM;2&X7^#%;;.:+"G\4$+V.:HO=!(W9&-V4P-RTQH@2H>$Y
MWT,%LY!@V?[*E))%TE-4%6F#MFU\IY?)CL0ED!,QU&7%XH%405N23Q+ (RW'
M)B)V 9@TF/9F8FCM'GJB*>Q4!8XZWXFAB@:TQP]]4'#PPTX37[T!^)(@P3RI
M(8%AI5%<9Y=XJUYD/^@#NA6,P$D,Z1J&!9L")]33_(NO0V< QGOSB3C,A^'K
MU5#7J0IM*:H0:#.3?]W],6Z1@$[&;0. 1"C[*>,;U/2GBN8"OK3+MQ?\4P>"
M09^.)A?'@OTB4XHZN(+;>V@?Z!HP'\[0T]H(G>6 A ]\:QQ$V(;N6U 2MT80
M$E=J,+<3'+/%--96[/%9HL,)W8*MY/4K/)T>'4$3*&O=NC:;JO04=ZZ>M^H8
M@!=7M> D32KD@MOYFL7?EL51OG9T7 "969*I&.&S-7Y:J3"!W:\SI()BD7L'
MP V_+X87UIO,'N&"FPR-&_1#7072=C!H ?/Q]YVG]PS$!91BC +W%#?";9M*
M71@)@R_HY5OD&:YE5VD!66>2&>_L&)(O/XSD/=_A]JQH$=#7U/D>MC&Z*V[$
MP@$S  0UK,XC6L!$)Y,A0:H8?B:FTNER06;0D9";?(]75<<:^S:VD/7,=9R$
M7]AV>)1@ A8L@[\<W!U!T<\90&8M^ 7O<1Z/5O@F-IYQBS::A!-IVX=R<V,<
M3 ] $H%/@!6&@9>#.0Q6F&-RI$1&=D>9UENDEUE@0&>6(BO4Y+'40.$*SQ7F
M@MLQ$42T&#6%2XN/D()QRC?RW<=)W3"5P?U?<(23I.[5U+7 ^ 7;P/(Z1^&#
M;QF*Y0:U"OU;W$RGFH/F10[,:!$0R:7CPL'(9?A$SR1;1U<;_O1NZL)'1N/$
M3:SB-K?F-1$F>6@JF"\ N -AB>B"BL$H&%9;RXPW@_L<PX_<P3ID+9.ONEBN
M8M2I T,ECB2'*DIX97&0\3*HFX"VD(I!W8!!Q#TG:&4KXOI(^([&"FF;>D]\
M1(4&/^/"Q\*>>JZO)_PM+H>P%NY6^M;4E*AVX-9!Y19S@0+;4T3,*4!^QQ(N
M5**5W:5<]WK17J'&6X'AR -XX #/B!<J;<+M<#& ))F.+] ,JL@!B]JZ\,G8
MT&5N@5/99=E@UFN"?ULE&:+J"2H6F4W4Z@;4'*+@,&'#[[KC!2E0BD$]X;N/
M\Q*G#C_2S\6>8H\P7AU$&*91O&).T/Q2R0[#)M #P,'!QID%I;Q!/.B6BVR)
M\1B,[@+@Z1:/Z]QPS,<CBP]-SKYLFA9GX(^5<S-$9FWJJ,*C17,GXFO7VV)_
M6=A!7E5=@K\MS];'WA7-\2GJ0FP\$.'[;FX L\@8QL/XEDU4AG<"HU'R)/&-
MO.B&5$7N(7>$IE6-CVT03O("1D $U0;26J@'!<P361%1-]S%XXPIS"&TF(2/
MC22N<WR(E]Y#N%.TOJ[VO>VN<9NN!2:TZ1BVQ/,O+:@)MM (G#5,B-3-#M64
M!W??)HH0O2WB ?/8>K+5\W"SN3'68X ;SMK408KA>4:X1X0@8!>Z(T2>6!LW
MGN2]-TDE3_9YT0X/FBAMD( TQ,ZB"VR+\8V3\97X'!G#\S/XLNMDO76RWCI9
M[Q.HW[D!P6C&0OS1= 0_(.\FZ.CP#V;E\PBU:;MJC&?>,W</*AQ&1,WWC#CB
MBZ'$HR/8"=\0DW1#84+&BZ@CSZI90M@Q[X<=XXLTSH9CE@NTST5BGN& 9P2Y
M(OJY-G[?#.Z*2UH\[^?9ZUH(8MF<+8"-JHYIHL$G'K*87.XI\6T>6?>#[7P[
MV% T5P!$8&J!)N^88+')J%]T<Q=#\S8 = 4&%]["=4(U"]!"#F!L8)[_T!XH
MC@,*)GJ<G)R<^QQ@,I7RD*/+S7U L0S^Y%@X!*,<WOX2;FV[P8V7Y9B=L [(
M@3,QQ?'$@,T-C/!%JG#TJ):.MY$QV<M0"L11W)-@B-K6: YW80JL$$R1# T_
M2V'-=^^9"!V.%?*4+9D'-C  #N3*@P94TX#X)<]WPJA'*#7#(\LDJ42X*=H'
M1NTX(2W \)L;I=(DRYLA5E_O9JT0W &1;2].9&Y*Q!L367;%B(S_6]@1CUP]
MOFX)477%*.Z-)^&?R<DFTSE2Q6QI5ZE3<@"6M62#@>R=;3T+W;&)8=3P!Y$P
M@]_:[<0^57E>>;/+F$TJF,G2<7,0L>/@[<.W.]KS@0Y8+=]U4S1Q]AT7"E/V
M3=F3'-%LX,#QL6#=H(W-MP>00@@_M+76'>]^>&X'U^&,AR5K/.:]YJ%WT-$\
M66U,[?+@@*=[HVK<P63?\6383#+C)\.Z7432:<4V,D_^5[WC9E[F"ZA<=T<O
ME*D2/G##7\@93X#Q(_A-<01F'US!GH-N5I^1<\["N"WBOKP3/+GCO<'CO;SC
MND"A332QN>>E!^;SXH10 ,03!HR C^>'_*U"S$B&WOSAHYN#(@/'#?K+"EZT
MH,GK@PE+%#DE%#F!&>#[HE[>/S<)ERR'WO<2E/55VQ& 7W35-LQT5DAH2Y[_
M]M[8\,M_1/9E+#)G9L]UJ(+''P-T?(KKY^9<A;9RZ_E)[P"<0Z9!HO.*+\T\
M5J.D:^+=7VR826227;L7/?0?SA</GX$="^VY!U1I3X]F/?"OKW,Q &A,6B:?
MC-K6++\"BS"'7?+OP?(>BW9MV[!V4ZG!8)"TF)3LZ/U4Q92ZP#96BLD=:J:
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M*$^_8$J[;];N?8Z!>^;:K&KE&0&K^V#D'27GJ5/Y#1RFS)+%NNB7+;TD8)$
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MJP^ZHOOZB5QC<<_H[:<+A%BX7?"^7Y&LJ[_7WV7'S0_S'TGI(W\"4$L#!!0
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M1M>8K+5]2>,6 G5C, DEK:6._88L@CAA\K9],0]JZ,8 O>FNO]&V.A9HQ4Y
MT\4A.%J4@U 198FCXRA:X_"&K"AKPJ<J,TV-SJ0*2UGC%",:8R :J1:E8DM$
M_&.-&9_,AB^M4-24IKD K*IH*#*GZ-![ P$IY'89N64XB@/1@;5"4I<:O]P
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M:'1M4$L! A0 %   " @ [('14O/1*W#O"0  TC(   D
MRX4  &5X-2TQ+FAT;5!+ 0(4 !0   @( .R!T5+P";9]! P  +0X   *
M             .&/  !E>#DY+3$N:'1M4$L! A0 %   " @ [('14@$2N?_
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2      D "0 ? @  P^D

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
